INDEX

Page references followed by t and f indicate tables and figures, respectively.

A
Abandonment, 105, 106t
Abciximab, 419
Abdominal aortic aneurysm, 430
 indications for repair, 430
 screening for, 78t, 81
Abdominal ultrasonography, 78t
ABI (ankle-brachial index), 393
Abiraterone, 596
Abnormal Involuntary Movement Scale (AIMS), 358–359
Abstinence
 from nicotine, 376
 pharmacotherapy support for, 374–376, 375t
 from substances of abuse, 369–370
Abuse. See Mistreatment
ACA (Affordable Care Act), 37, 49
Acamprosate, 374–376, 375t
Acarbose (Precose), 572t
ACA (Affordable Care Act), 37, 49
Abandonment, 105, 106t
Abstinence
 from nicotine, 376
 pharmacotherapy support for, 374–376, 375t
 from substances of abuse, 369–370
Abuse. See Mistreatment
ACA (Affordable Care Act), 37, 49
Acamprosate, 374–376, 375t
Acarbose (Precose), 572t
ACC. See American College of Cardiology
Accidents, 4–5, 6
See ACC.
American College of Cardiology
Aclidinium, 412t
Acute care, 169–170
Acute kidney injury, 465–467
Acute interstitial nephritis, 466
Acute ischemic stroke, 525–526
Acute myeloid leukemia, 596–597
Acute pain, 128
Acute Postoperative Pain Management, 445–446
Acute Physiology and Chronic Health Evaluation scoring system (APACHE III), 33–34
Acute renal failure, 467
Acute tubular necrosis, 466
Adaptive behavioral difficulties, 381
Adaptive methods, 162, 164–165
Addiction, 134, 369–377
 alcoholism, 246t
 definition of, 130t
 magnitude of the problem, 370–371
 pseudoaddiction, 130t, 134
 substance abuse, 369–370
 treatment of, 374–376, 375t
ADEs. See Adverse drug events
ADLs. See Activities of daily living
Adult Protective Services (APS), 108
Adult day care, 185
Adult foster care, 188
Advance directives, 30, 35–36, 66–67, 239
 living wills, 31
 recommendations for, 79t, 84
Adverse drug events, 91–92, 92t
 definition of, 91
 in-hospital, 146–147
 risk factors for, 91, 91t
Aerobic activity recommendations, 69, 70–71, 71t, 350
AF. See Atrial Fibrillation
Affective disorders, 246t
Aerobic activity recommendations, 69, 70–71, 71t, 350
AF. See Atrial Fibrillation
Affective disorders, 246t
Aldosterone, 547
Alcohol abuse, 134
 Alcoholism, 246t
 Altered mental status, 304–305
 Alcohol withdrawal, 304
 Alcohol withdrawal syndrome, 304
 Alcoholics Anonymous, 304
 Alcoholic hepatitis, 304
 Alcoholic liver disease, 304
 Alcoholics in the elderly, 304
 Alcoholism, 246
See AA.
American College of Sports Medicine
American Diabetes Association (ADA), 569
American Geriatrics Society (AGS), 493
American Urological Association (AUA), 480
American Academy of Family Physicians (AAFP), 48
American Academy of Women’s Health (AAWH), 48
American Heart Association (AHA), 48
American Osteopathic Association (AOA), 48
American Psychological Association (APA), 49
American Society for Nutrition (ASN), 49
American Society of Human Genetics (ASHG), 49
American Society of Clinical Oncology (ASCO), 49
American Society for Nutrition (ASN) 233–234
American Society of Parenteral and Enteral Nutrition (ASPEN), 49
American Society for Nutrition (ASN) 233–234
American Society of Parenteral and Enteral Nutrition (ASPEN), 49
American Society of Nutrition (ASN), 49
American Society for Nutrition (ASN) 233–234
American Society of Parenteral and Enteral Nutrition (ASPEN), 49
American Society of Nutrition (ASN) 233–234
rate of living theory of, 11t, 12
stem cell/progenitor cell theory of, 11t, 13
telomere theory of, 11, 11t
theories of, 9–12
Agitated delirium, 312–313, 312t
Agitation
Cohen-Mansfield Agitation Inventory (CMAI), 297
in dementia, 296–297, 304
intermittent, 304
Agoraphobia, 355, 355t
AGS, See American Geriatrics Society
AHA, See American Heart Association
Aid to Capacity Evaluation (ACE), 30
AIDS (acquired immunodeficiency syndrome), 168, 547
AIMS (Abnormal Involuntary Movement Scale), 358–359
AKI (acute kidney injury), 465–467
Albumin, 235
Albuterol, 411, 412t
Alcohol
benefits of consumption, 371
and delirium, 311t
and incontinence, 245t
nutrient interactions, 235, 235t
and risk of osteoporosis, 274, 274t
Alcohol abuse
at-risk drinking, 369, 374–376, 375t
clinical settings, 371
counseling interventions for, 79t, 82
cultural and demographic factors, 371
heavy drinking, 370
low-risk or moderate drinking, 370
magnitude of the problem, 370–371
problem drinking, 374–376, 375t
Alcohol dependence, 374–376, 375t
Alcohol detoxification, 374–376, 375t
Alcohol-related dementia, 372
Alcohol Use Disorders Identification Test (AUDIT), 82
Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) questions, 372, 374t
Alcoholics Anonymous, 373
Alcoholics Anonymous, 373
Alcoholics Anonymous, 373
Alcoholism
and incontinence, 246t
Michigan Alcoholism Screening Test (MAST)—Geriatric Version, 372
Alendronate, 278, 279t
ALFs (assisted-living facilities), 167, 187
Allergic conjunctivitis, 203–204, 204–205, 204t
Allodynia, 130t
Alosetron, 456
α-Adrenergic agonists
adverse drug events, 92, 92t, 209, 210t
and incontinence, 245t
α-Adrenergic antagonists or blockers
adverse drug events, 92, 92t
for benign prostatic hyperplasia, 480, 480t
for hypertension, 444
and incontinence, 245t
Alprazolam, 93, 311t
Alprostadil, 493–494, 493t
ALS (amyotrophic lateral sclerosis), 534–535
Alteplase, 525–526
Alternative medicine, 97–103, 98
American Academy of Pediatrics (AAP), 236
American Academy of Ophthalmology, 202
American Academy of Otolaryngology–Head and Neck Surgery, 408–409
American Academy of Pediatrics (AAP), 190
nutrient interactions, 235, 235r
peroperative, 110, 114r
for prostatitis, 487

Anticholinergics
adverse drug events, 92, 92r, 250
for COPD, 411, 412r
and delirium, 309–310, 311r
and incontinence, 245r
for nausea, 124r
for Parkinson disease, 529

Anticoagulation therapy
for Parkinson disease, 529
and incontinence, 245
and delirium, 309–310, 311r
for COPD, 411, 412
adverse drug events, 92, 92

Anticonvulsants
adverse drug events, 92, 92r
cessation before surgery, 110, 115r
peroperative, 110, 114r

Antidepressants
for depressive features of anxious or fearful behaviors, 362, 363r
therapeutic strategies for, 365, 365r

Antipsychotics
adverse drug events, 92, 92r
and delirium, 309–310, 311r
dosing and adverse events of, 338, 359r
for hypersexuality, 303–304
and incontinence, 245r
interventions for preventing falls with, 268r
to stabilize mood in mania and bipolar depression, 345, 348r

Antithrombotics
for ACS, 419
for stroke prophylaxis in AF, 427

Anxiety disorders, 352–356
classes of, 352–354
comorbidty, 354–355
depression with anxiety, 354
features of anxious or fearful behaviors, 362, 363r
generalized anxiety disorder, 354, 355, 355r
and incontinence, 246r
marked anxiety, 354
and medical disorders, 354–355, 355r
pharmacologic management of, 355–356
psychologic management of, 356
treatment strategies for, 355, 355r

Aortic regurgitation (AR), 423
clinical features and treatment of, 424r
diagnosis of, 423
epidemiology of, 423

Aortic stenosis (AS), 423
clinical features and treatment of, 424r
diagnosis of, 423
prevalence of, 423

APACHE III (Acute Physiology and Chronic Health Evaluation scoring system), 33–34

Apathetic thyrotoxicosis, 552
Aphthous ulcers, 404–405, 405r
Apidra (insulin glulisine), 574r
Apixaban, 427
Apolipoprotein E gene (APOE), 285
Appetite stimulants, 238
APS (Adult Protective Services), 108
Aqueous outflow facilitators, 210r
Aqueous suppressants, 210r
AR. See Aortic regurgitation
ARBs. See Angiotensin-receptor blockers
Area Agencies on Aging, 294
Arformoterol, 412r
Aripiprazole
dosing and adverse events of, 358, 359r
to stabilize mood in mania and bipolar depression, 348r

Arthritis
bradyarrhythmias, 428–429
cardiac, 424–429
cardiac syncope due to, 227, 228r
indications for permanent pacemaker implantation, 428–429, 429r
supraventricular, 427–428
ventricular, 428
Arterial ulcers, 392, 392r
Arteriosclerotic parkinsonism, 257
Arteriovascular disease, 246r
Arteriovenous malformation, 456
Arthritis, 495
differential diagnosis of, 495, 496r
of elbow, 497
exercise for, 499
of foot, 522
general management of, 499, 500
of knee, 498
osteoarthritis, 500–501, 501f
prevalence of symptoms, 4, 5f
psoriatic, 391
rheumatoid arthritis, 501–502
of wrist, 497
Arthritis Foundation, 132
Arthrocentesis, 496, 503–504
Arthroplasty, total hip and knee, 160–161
Arthroscopic debridement, 501
Artificial feeding, 239
Artificial sphincter, 251
AS. See Aortic stenosis
ASA (American Society of Anesthesiologists), 109–110, 111
Asenapine
dosing and adverse events of, 358, 359
for psychosis in dementia, 302
Asian Americans
burning mouth syndrome in, 404
cancer incidence, 589
eンド-of-life care, 119
nursing-home population, 166
Aspiration, 241
Aspiration pneumonia, 156, 241
Aspirin therapy
for acute coronary syndrome, 419, 420
adverse drug events, 92, 92
for atrial fibrillation, 426–427
for chronic CAD, 421
for diabetes mellitus, 569
low-dose, 586
perioperative, 110, 114
for peripheral arterial disease, 430
preventive, 79, 85
for stroke prevention, 525
Assessment, 52–57. See also Screening of amputation, 162
of behavioral problems in dementia, 297–298
Berg Balance Test, 265
brown-bag evaluation, 94
of cancer patients, 590
cardiac risk assessment for noncardiac surgery, 110, 112

cognitive, 55
comprehensive eye examination, 202
comprehensive geriatric assessment (CGA), 83, 157–158, 189–190
Confusion Assessment Method (CAM), 146, 305–306, 307
Confusion Assessment Method for the Intensive Care Unit (CAM-ICU), 306, 307
daily evaluation of hospitalized patients, 149
determination of capacity, 29
Delirium Rating Scale 1998 Revision, 306
executive function testing, 55
falls risk assessment, 79
vertebral fracture assessment (VFA), 276–277
vision testing, 79, 83–84, 202
Assessment instruments, 154
Assisted-living facilities, 167, 187
Assistive devices, 6–7, 162–163
Assistive listening devices, 216–217
costs of, 217–218, 218, 219
Asthma, 409–410
Asthma action plans, 410, 410
At-risk drinking, 371, 374–376, 375
At-risk substance use, 369
Atherosclerosis
in diabetes mellitus, 569–570
prevention and management of, 569–570
ATN (acute tubular necrosis), 466
Atorvastatin, 419
Atrial fibrillation, 425–427
clinical features, 425
diagnosis of, 425
in hospitalized patients, 143
interventions for, 143
management of, 425–427
prevalence of, 425
Atrial natriuretic hormone, 558
Atrioventricular block, 428–429, 429
Atrophy
multiple system, 530–531, 530
urogenital, 473–474
Attention
inattention, 306, 307
tests of, 306, 307
Attention Screening Examination, 306
Attitudes
regarding disclosure and consent, 66
toward advance directives, 66–67
toward North American health services, 64–65
Audiometry screening, 79, 84, 215
AUDIT (Alcohol Use Disorders Identification Test), 82
AUDIT-C (Alcohol Use Disorders Identification Test-Consumption), 372, 374
Auditory system changes, 212
Autoimmune skin conditions, 387–392
Automobile accidents, 56
Autonomy, 23
in dementia, 35
respect for, 28
Avanafil, 492–493, 493
Avandamet (rosiglitazone and metformin), 573

pain behaviors in cognitively impaired, 130–131, 132t
self-injurious, 380
socially inappropriate, 35
Behavioral health management, 349t, 350
Behavioral interventions. See also Cognitive behavioral therapy for dementia care, 298–299, 299t for depression, 349t, 350 for frailty, 200 for insomnia, 303, 303t for sleep problems, 322–323 for urinary incontinence, 249–250, 251, 252
Behavioral Pathology in Alzheimer Disease Rating Scale (BEHAVEAD), 297
Behavioral problems assessment of, 297–298 clinical features of, 296–297 in dementia, 296–304, 299–300, 300t differential diagnosis of, 297–298 disorders in aging adults with mental retardation, 381 manic-like features of, 300–301, 301t medications to treat depressive features of, 299, 300t treatment of, 298–299, 299–304 Beliefs, self-efficacy, 24 physical and mental health impacts of, 24, 24t strategies effective for strengthening, 24 Bell’s palsy (facial nerve palsy), 548 BENZAMIDE, 435t Beneficence, 28, 30t BENZODIAZEPINES, 412t Bed-pressure positioning devices, 331 Bedsores, 328t See also Pressure ulcers BEHAVEAD (Behavioral Pathology in Alzheimer Disease Rating Scale), 297 Behavior(s) adaptive, 381 anxious or fearful, 362, 363t challenging, 379 dramatic, emotional, or erratic, 362, 363t healthy behaviors, 27 maladaptive, 382 odd or eccentric, 362, 363t and delirium, 309–310, 311t dependency on, 373, 374–376, 375t drug interactions, 93, 93t for insomnia, 324, 325t interventions for preventing falls with, 269t for sleep problems, 321, 324, 325t BENZTROPINE, 311t Bereavement therapy, 349t, 350 Berg Balance Scale (Test), 258, 265 Berger disease, 464 Best-interest standard, 31 β-Adrenergic agonists, 411, 412t β-Adrenergic receptors, 238t β-Blockers for acute coronary syndrome, 420 adverse drug events, 92, 92t, 210t for anxiety disorders, 355, 355t for atrial fibrillation, 426 for chronic CAD, 421 for heart failure, 435–436, 435t for hypertension, 444 perioperative, 110, 114t β-Carotene, 206, 237 Betamethasone, 503–504 BEVACIZUMAB, 207 Bi-level positive airway pressure (BiPAP), 319 Bibliotherapy, 349t, 350 Biguanides, 571, 572t Biliary disease, 451 Bio-identical hormonal products, 473 Bioavailability, 87 Biofeedback, 100–101 Biologic therapy, 591–593 Biologically based methods, 98, 98t Biology, 9–19 Bipolar depression, 345–349, 348t Bipolar disorder, 342–343 type 1, 343 type 2, 343 Bisacodyl (Dulcolax), 453t Bisoprolol, 435t Bisphosphonates adverse drug events, 92, 92t, 279–280 for osteoporosis prevention and treatment, 278–280, 279t for persistent pain, 138 special concerns, 282 Bivalirudin, 419 Black Americans alcohol use, 371 cancer diagnosis and survival, 589 cancer incidence, 589
Index 605

depression in, 340
diabetes mellitus, 566
dual eligibles, 42
end-of-life care, 119–120
hypertension, 440
leading causes of death, 4–5, 6
life expectancy, 3, 3t
nursing-home population, 166
oral cancer, 403
perceived health, 4, 5t
poverty rates, 3
pressure ulcers, 329
risk factors for depression, 340
self-reported functional limitations, 6
social status, 23

Black cohosh, 102
Black hairy tongue, 405, 405f

Bladder control difficulties, 166, 167

Bladder contractions, uninhibited, 245–246
Bladder control difficulties, 166
Bladder diaries, 248, 248t
Bladder obstruction, 246
Bladder training, 249

Bleeding
gastrointestinal, 456
vaginal, 477, 477f

Bleeding diatheses, 584

Blepharitis, 203–204, 204t

Blindness
causes of, 202, 203t
definition of, 202
irreversible, 203t
reversible, 203t

Blood glucose screening, 78t

Blood pressure. See also Hypertension;

Hypotension
classification of, 440, 440t
screening, 78t

Blood pressure monitoring
ambulatory, 441
indirect or cuff, 441

BMI (body mass index), 84, 234

Body-based methods, 97, 98
Body composition changes, 233
Body dysmorphic disorder, 366
Body language, 64
Body mass index (BMI), 84, 234
Body size classification, 234

Body weight, 72

Bone
age-related changes, 14t, 15
age-related pathologies, 18t
musculoskeletal complaints, 495
Bone-anchored hearing aids (BAHA), 219

Bone disease
calcium, phosphorus, and renal bone
disease, 468–469
Paget disease of bone, 557–558
Bone formation changes, 272
Bone infections, 546–547
Bone loss, 272. See also Osteoporosis
Bone mineral density testing, 275–276
diagnostic criteria for osteoporosis,
271
indications for, 276, 276t
recommendations for, 276
serial measurement, 282
WHO definitions, 271, 272t
Bone remodeling, 272
Bone-specific alkaline phosphatase, 275,
276t
Bone turnover, 277
Borderline personality disorder
features of, 362, 363t
therapeutic strategies for, 365, 365t
Bordetella pertussis infection, 409
Boston Naming Test, 288
Botulism toxin, 456
Bradycardia, 428–429, 429
Bradyarrhythmias, 428–429
Braden Scale, 329
Bradydysrhythmias, 428–429
Bradykinesia, 528
Brain imaging studies, 296
Breast cancer, 594–595
adjunct hormonal treatment of, 596
CAM for, 102–103
characteristics of, 588–589
ethnic and racial differences in
incidence, 587
hormonal therapy for, 591
metastatic, 596
racial differences in diagnosis and
survival, 587
screening for, 77
Breast self-examination (BSE), 77
Breathing disorders, sleep-related, 318–
319, 321
Breathlessness, 125–126
Bright light, 320, 321, 322–323, 323t
Brimonidine, 210t
Bone disease
calcium, phosphorus, and renal bone
disease, 468–469
Paget disease of bone, 557–558
Bone formation changes, 272
Bone infections, 546–547
Bone loss, 272. See also Osteoporosis
Bone mineral density testing, 275–276
diagnostic criteria for osteoporosis,
271
indications for, 276, 276t
recommendations for, 276
serial measurement, 282
WHO definitions, 271, 272t
Bone remodeling, 272
Bone-specific alkaline phosphatase, 275,
276t
Bone turnover, 277
Borderline personality disorder
features of, 362, 363t
therapeutic strategies for, 365, 365t
Bordetella pertussis infection, 409
Boston Naming Test, 288
Botulism toxin, 456
Bradycardia, 428–429, 429
Bradyarrhythmias, 428–429
Braden Scale, 329
Bradydysrhythmias, 428–429
Bradykinesia, 528
Brain imaging studies, 296
Breast cancer, 594–595
adjunct hormonal treatment of, 596
CAM for, 102–103
characteristics of, 588–589
ethnic and racial differences in
incidence, 587
hormonal therapy for, 591
metastatic, 596
racial differences in diagnosis and
survival, 587
screening for, 77
Breast self-examination (BSE), 77
Breathing disorders, sleep-related, 318–
319, 321
Breathlessness, 125–126
Bright light, 320, 321, 322–323, 323t
Brimonidine, 210t

British Geriatrics Society (BGS), 266–267,
269
Bronchodilators, inhaled, 411, 412t
Brown-bag review, 94, 309
BSE (breast self-examination), 77
Budesonide, 412t
Bulk laxatives, 435t
Bullous pemphigoid, 389–390, 389f

Buspar, 219
Buspirone
for anxiety disorders, 355, 355t
for depression, 344, 346t
Busulfan, 585–586
Butorphanol, 138
Bydureon (long-acting exenatide), 573t
Byetta (exenatide), 573t
Bypass surgery, 422–423

C

C-reactive protein, 418
Cachexia, 124
CAD. See Coronary artery disease

Caffeine, 268t

CAGE (Cut down, Annoy, Guilt, Eye-
opener) questionnaire, 82, 372, 374t
Calcaneal spur, 515t
Calcitonin, 279, 280
Calcitriol, 273

Calcium
coronary artery content, 418
deficiency of, 273
dietary intake, 278
disorders of metabolism of, 554–558
drug interactions, 235, 235t
foods that contain, 278
homeostasis changes, 554, 555
RDIs for adults ≥ 71 years old, 234
and incontinence, 245–246

Calcium-containing antacids, 92, 92t

Calcium channel blockers
adverse drug events, 92, 92t, 235
for chronic CAD, 421
drug interactions, 93, 93t
for hypertension, 444
and incontinence, 245t, 250

Calcium-containing antacids, 92, 92t

Calcium channel blockers
adverse drug events, 92, 92t, 235
for chronic CAD, 421
drug interactions, 93, 93t
for hypertension, 444
and incontinence, 245t, 250

Calcium-containing antacids, 92, 92t

Calcium-containing antacids, 92, 92t
Calcium pyrophosphate dihydrate deposition disease, 503–504
Calcium supplements
for osteoporosis prevention and treatment, 274, 274t, 291
preventive, 79t, 85
California Healthcare Foundation, 569
CAM. See Complementary and alternative medicine
CAM (Confusion Assessment Method), 146, 305–306, 307t
Canalith repositioning procedure, 224t
CAM (Confusion Assessment Method), 102–103
Complementary and alternative medicine
see California Healthcare Foundation, 569
preventive, 79t
physical activity recommendations
ovarian cancer, 80
oral cancer, 402–403
oral, 404, 404f
skin, 388–389, 389f, 394
Canes, 163, 163t
Capacity for consent, 28, 29–32
Capsaicin cream, 500
Capsicum frutescens (cayenne), 100
Captopril, 435t
Carbamazepine (Tegretol, Epitol)
adverse drug events, 92, 92t
for alcohol detoxification, 374–376, 375t
for behavioral disturbances in dementia with manic-like features, 301, 301t
for dementia, 294
for epilepsy, 534t
for persistent pain, 135t, 138t
to stabilize mood in mania and bipolar depression, 348t
Carbidopa-levodopa
for Parkinson disease, 528
for periodic limb movement disorder, 320
for restless legs syndrome, 320
Carbonic anhydrase inhibitors, 210t
Cardiac arrhythmias, 424–429
epidemiology of, 424–425
syncpe due to, 227, 228t
Cardiac assessment, preoperative, 109–110
Cardiac disease
dearth due to, 4–5, 6t
with developmental disabilities, 382–384, 383t
prevalence of, 4, 5f
Cardiac rehabilitation
for acute coronary syndrome, 420
for chronic CAD, 423
Cardiac resynchronization therapy, 438
Cardiac risk assessment for noncardiac surgery, 110, 112f
Cardiac stress testing, preoperative, 110
Cardiac syncope
due to arrhythmia, 227, 228t
predictors of, 229, 229t
Cardioembolic stroke, 525
Cardiovascular diseases and disorders,
415–432
activity recommendations for,
71t
CAM for, 100–101
epidemiology of, 415, 415t
and incontinence, 246t
prevalence of, 415, 415t
Cardiovascular risk factors, 417–418, 430
Cardiovascular system
age-related changes in, 14t, 15t
415–417, 416t
age-related pathologies, 18t
indications for revascularization, 110, 111t
perioperative therapy to reduce complications, 110, 114t
postoperative management of problems, 113–115
preoperative assessment and management of, 109–110
Care Area Assessments, 239
Care plans, 60
Care systems, 142–193
Care transitions, 178f
barriers to safety, 178
communication for, 180
definition of, 177
discharge destinations, 179
planning for, 117
questions to assist with, 180
steps to improve, 180
suboptimal, 177–183
target measures for improvement, 180
venues of care, 179
Caregiver Abuse Screen, 84
Caregivers
communication with, 180
dementia caregiver counseling, 349t, 350
education of, 291
family caregivers, 7, 185
role of older adult with, 107
support for, 184, 291, 294
Caregiving, 21–22
risk factors for inadequate or abusive caregiving, 104, 105t
Carotid sinus hypersensitivity, 268t
Carpal tunnel syndrome, 497–498
Carvedilol, 435t, 444
Castrate-resistant prostate cancer, 596
Cataracts, 205–206, 268
Cataracts, 203
Catastrophic insurance, 41
Catechol-O-methyltransferase inhibitors, 529
Catheter care, 252–253
Catheters, 252–253
Cavus foot, 514–516
CBE (clinical breast examination), 77
CBT. See Cognitive behavioral therapy
CCRCs (continuing-care retirement communities), 188
Ceftriaxone, 548
Celecoxib (Celebrex), 135

Center for Medicare and Medicaid Services (CMS), 37

Center for Excellence on Elder Abuse & Neglect, 104

Centers for Disease Control and Prevention (CDC), 543

Centers for Medicare and Medicaid Services (CMS), 37

Federal Coordinated Health Care Office, 42–43

Medicare Prescription Drug Plan Finder, 41

Quality Indicator Survey (QIS) process, 171

Quality measures for nursing homes, 170–171, 170t

Central artery occlusion, 204t

Central pain, 130t

Central sleep apnea, 318

Cephalaxin, 93, 93t

Cerebral insufficiency, 293

Cerebrovascular disease, 523–526

Cerebral parenchymal injury, 527–528

Cerebral palsy, 529

Cerebrospinal fluid (CSF), 530–531

Cerebellar atrophy, 532

Cerebral infarct, 533

Cerebral ischemia, 534

Cerebral revascularization, 535

Cerebral venous sinus thrombosis, 536

Cerebral edema, 537

Cerebral hemorrhage, 538

Cerebral inflammation, 539

Cerebral myelopathy, 540

Cervical cancer screening, 80

Cervical myelopathy, 259

CGA. See Comprehensive geriatric assessment

Chalazion, 204

Charles Bonnet syndrome, 360

Checklist of Nonverbal Pain Indicators, 131

Chemical restraint, 35

Chemoembolization, 57

Chemotherapy, 58–59, 592t

Cherry angiomas, 395

Chericys-Stokes breathing, 318

Chinese culture, 119

Chiropractic services, 97–98

Chloral hydrate, 311t

Chloralhydrate, 311t

Chloride channel activators, 453t

Cholecalciferol (vitamin D3) supplements, 555–556

Cholesterol, 235

Cholesterol screening, 78t

Cholesteramine

adverse drug events, 92, 92t
for diarrhea, 123

Choline magnesium trisalicylate, 500

Cholinesterase inhibitors

adverse drug events, 92, 92t
for dementia, 292–293
and incontinence, 245t

Chondrocalcinosis, 503, 503t

Chondroitin, 99

Chorea, 531, 532

Choroidal neovascularization, 206, 207, 207f

Chloral hydrate, 311

Chloral hydrate, 311

Chloroprazin, 124

Ciprofloxacin, 455

Citroma (magnesium citrate), 453

t

Clarithromycin, 93, 93t

Clindamycin, 455

Climacteric, 119

Clonazepam (Klonopin), 444, 473

Clock-drawing test, 55, 83

Cockcroft-Gault equation, 89, 111–113, 460

Cochlear implants, 219–220, 219t

Cockcroft-Gault equation, 89, 111–113, 460

Cognitive assessment, 55

Mini-Cog Assessment Instrument for Dementia, 55, 83, 145, 286, 287t

Mini–Mental State Examination (MMSE), 29–30, 55, 83, 145, 286, 287t

Montreal Cognitive Assessment (MoCA), 55, 286, 287t

Cognitive assessment, 55

Mini-Cog Assessment Instrument for Dementia, 55, 83, 145, 286, 287t

Mini–Mental State Examination (MMSE), 29–30, 55, 83, 145, 286, 287t

Montreal Cognitive Assessment (MoCA), 55, 286, 287t

rapid screening followed by assessment and management, 52, 53t

screening instruments for, 286, 287t

Clinical breast examination (CBE), 77

Clinical feasibility, 60

Clinical management, 58

Clinical settings

medical director responsibilities for leadership in, 171t, 172–173
promoting physical activity in, 73
rehabilitation services, 153t

Clinker theory, 12

Clock-drawing test, 55, 83

Clomipramine, 355, 355t

Clonazepam (Klonopin)
for persistent pain, 135t, 138
for REM sleep behavior disorder, 320

Clonidine, 444, 473

Clopidogrel
for acute coronary syndrome, 420
for chronic CAD, 421
for peripheral arterial disease, 425
for stroke prevention, 525

Clostridium difficile infection, 457

Clotting factor deficiencies, 585

Clozapine
and delirium, 311t
dosing and adverse events of, 358, 359t
for Parkinson disease and hallucinations, 360
for psychosis in dementia, 301–302, 302t

CMAI (Cohen-Mansfield Agitation Inventory), 297

CMI (Center for Medicare and Medicaid Innovations), 37, 43, 49

CMS. See Centers for Medicare and Medicaid Services

Coagulation, 584–585. See also Anticoagulation

Cochlear implants, 219–220, 219t

Cockcroft-Gault equation, 89, 111–113, 460

Code of Federal Regulations, 170

Coenzyme Q10, 98, 99, 100

Cognitive assessment, 55

Mini-Cog Assessment Instrument for Dementia, 55, 83, 145, 286, 287t

Mini–Mental State Examination (MMSE), 29–30, 55, 83, 145, 286, 287t

Montreal Cognitive Assessment (MoCA), 55, 286, 287t

rapid screening followed by assessment and management, 52, 53t

screening instruments for, 286, 287t

Index 607
Cognitive behavioral therapy
for anxiety disorders, 355, 355t
for depression, 349t, 350–351
for pain, 132
for sleep problems, 322, 323t, 325
Cognitive bibliotherapy, 349–350
for sleep problems, 322, 323
for pain, 132
for depression, 349
for anxiety disorders, 355–356
Cognitive behavioral therapy
in hospitalized patients, 145
in dementia, 287–288, 289t
interventions for preventing falls, 268t
mild, 287, 288t
pain assessment and treatment in,
130–131
pain behaviors in, 130–131, 132t
postoperative decline, 117
screening for, 79t, 83
sexuality and, 36
Cognitive rehabilitation, 289
Cognitive restructuring, 356
Cognitive training, 289
Cohen-Mansfield Agitation Inventory
(CMAI), 297
Colace (docusate), 453
Colchicine
for gouty attacks, 502
nutrient interactions, 235, 235t
Cold therapy, 499
Colitis, pseudomembranous, 457
Collagen, 251
Collapsing pes plano valgus foot, 514–516
Colon, 451–458
Colon cancer, 458, 595–596
CAM for, 103
prevalence of, 588
Colon cancer screening, 77–80, 78t
Colonic angiodysplasia, 456–457
Colonic ischemia, 457
Colonic polyps, 458, 458t
Colonic pseudo-obstruction, acute, 457
Colonoscopy, 77, 78t
Colorectal cancer, 458, 587
ethnic and racial differences in
incidence, 587
rational differences in diagnosis and
survival, 587
Colposuspension (Burch operation), 251
Combunox (oxycodone, immediate
release), 136t
Communication
addressing the healthcare provider, 63
addressing the patient, 63
discussing death, 120
discussing serious news, 121–122, 123t
end-of-life decision-making
conversations, 122
framework for, 121–122, 123t
with hearing-impaired people, 216, 216t
key techniques, 63
medical director responsibilities for,
171t, 172–173
patient–clinician, 52
respectful nonverbal communication,
64
strategies to enhance, 52, 53t, 216, 216t
strategies to facilitate, 52
teach-back method, 63
in transitional care, 180
unspoken challenging medical issues,
65
Community-acquired pneumonia, 542
Community-based care, 182–188
services not requiring change in
residence, 185–187
services requiring change of
residence, 187–188
Community Care Transitions Program, 45
Community-dwelling older Americans,
264f, 265
Competence
MacArthur Competency Assessment
Tool, 30
testamentary, 29
Complementary and alternative medicine,
97–103
definition of, 97
diversity of modalities, 97
efficacy of, 99
for managing illness in older adults,
99–103
safety issues, 98–99
usage patterns, 98, 98t
Complicated grief therapy, 349t, 350
Comprehensive eye examination, 202
Comprehensive geriatric assessment
(CGAs), 83
in primary care, 189–190
in rehabilitation, 157–158
Compulsions, 353, 355, 355t
Computed tomography, 497
COMT (catechol-O-methyltransferase)
inhibitors, 529
Concierge practice, 39
Conduction disturbances, 428–429, 429t
Conductive hearing loss, 213f, 214
Confusion Assessment Method (CAM),
146, 305–306, 307t
Confusion Assessment Method for the
Intensive Care Unit (CAM-ICU), 306, 307t
Conivaptan, 462
Conjunctivitis
allergic, 203–204, 204–205, 204t
viral, 203–204, 204t
Consciousness
altered level of, 306, 307t
sudden loss of, 228t
Consent
attitudes regarding, 66
capacity for, 28, 29–32
informed consent for research, 32
Conservatorships, 31
Constipation, 451–452
management of chronic constipation,
452, 452t
medications that may relieve, 452, 453t
opioid-induced, 134
postoperative-induced, 134
postoperative, 115–116
in terminal illness, 122
Consultation
outpatient, 189–190
proactive, 313
Continuing-care retirement communities
(CCRCs), 188
Continuity theory, 10
Continuous passive-motion (CPM)
machines, 161
Continuous positive airway pressure
(CPAP), 318, 319, 321, 413
Control-relevant intervention, 349t, 350
Conversion disorder, 366
COPD. See Chronic obstructive pulmonary
disease
Coping strategies, 24–25
Copper, 235, 235t
Corneal ulcers, 203, 204t, 205
Coronary artery calcium content, 418
Coronary artery disease, 418–419
chronic, 420–423
epidemiology of, 418–419
medical therapy for, 421–422
presentation and diagnosis of, 420–421
Coronary revascularization, 110, 111
tCorticosteroids
for COPD, 411, 412
for CPPD, 503–504
for idiopathic pulmonary fibrosis, 413
inhaled, 411, 412
ophthalmic, 205
perioperative, 116–117
for persistent pain, 138
stress doses, 116–117
Cosmetic surgery, 386–387
Costs
of assisted-living residences, 187
of assistive listening devices, 217–218, 218
of dementia care, 284
exercise benefits, 70
of glaucoma, 209
of health care, 37–50
of hearing aids, 217–218, 218
of nursing-home care, 168
of preventive health measures, 78–79
of preventive measures, 76
of suboptimal care transitions, 177
Cough
chronic, 409
in terminal illness, 126
Councils on Aging, 294
Counseling
on cancer screening and preventive health, 85–86
dementia caregiver counseling, 349, 350
family counseling, 313
healthy lifestyle counseling, 78–79, 82
for increasing physical activity, 73
COX-2 inhibitors
for musculoskeletal pain, 500
for persistent pain, 133
CPAP (continuous positive airway pressure), 318, 319, 321, 413
CPM (continuous passive-motion) machines, 161
CPPD (calcium pyrophosphate dihydrate deposition disease), 503–504
Creatinine clearance, 89, 460
Cross-cultural health care, 57, 61
Cross-over toe deformity, 517, 518
CRT (cardiac resynchronization therapy), 438
Crutches, 163
Cruzan v. Director, Department of Health of Missouri, 32–33
CSA (central sleep apnea), 318
Cultural aspects of care, 23, 62–68, 119–120
alcohol use, 371
Cultural differences, 29
Cultural identity, 63
Culture, 65
Curanderos, 98
Custodial care, 40
Cutaneous horn, 395
Cymbalta ( duloxetine), 135
cyproheptadine, 238
Cystic erosion, 515
tCysts, epidermal inclusion, 520
Cytochrome P450, 93, 93
tCytokine-modulating agents, 238
Cytokines, inflammatory, 238
Death
ability to predict time of, 33–34
interventions that can hasten, 33
leading causes and numbers of, 4–5, 6
overal care near, 119
Death with Dignity Act (Oregon), 33–34
Debridement, 332, 334
arthroscopic, 501
Decision making
approaches to, 65–66
cultural aspects, 62–68, 119–120
end-of-life, 32–35, 66
ETHNICS mnemonic, 67
in extended-care settings, 34–35
family decisions, 119–120
hierarchy of strategies, 30, 30
about institutionalization, 185
for patients who lack decisional capacity, 30–31
role of incapacitated patient in, 31–32
treatment decisions, 34–35
Decisional capacity, 28, 29–32
assessment of, 29
decision making for those who lack, 30–31
elements of, 29, 30
standardized tests of, 29–30
temporary loss of, 32
Decubitus ulcers, 328
Deep brain stimulation, 330
Deep venous thrombosis (DVT), 431
Deep venous thrombosis prophylaxis guidelines for, 115, 116
in hospitalized patients, 143, 148
Padua Prediction Score, 148
Defecography, 452
Degenerative joint disease, 382–384, 383
Dehydration, 234
Dehydroepiandrosterone (DHEA), 100
safety issues, 98, 99
supplements, 560
Delirium, 305–315
agitated, 312–313, 312
and dementia, 308
diagnosis of, 305–306, 307
Differential diagnosis of, 305–306
drugs to reduce or eliminate in management of, 310, 311
evaluation of, 309–313
guideline for, 314, 314
in hospitalized patients, 146
incidence of, 305
and incontinence, 246
management of, 309–314, 310
Memorial Delirium Assessment Scale, 306
models of care for, 313–314
neuropathophysiology of, 305–306
pharmacologic therapy for, 312–313, 312
postoperative, 117, 308–309
preoperative assessment and management of, 113
prognosis for, 305
psychotic symptoms in, 359
quiet, 306
in rehabilitation, 156–157
reversible causes of, 308, 308
risk factors for, 308
spectrum of, 306–308
in terminal illness, 124
Delirium Abatement Program, 314
Delirium Rating Scale 1998 Revision, 306
Delusional disorder, 359
Delusions, 343
  antipsychotic medications for, 301–303, 302r
definition of, 357
in dementia, 301–303, 302r
evaluation of patient with, 357
of infidelity, 359–360
mood-congruent, 359
of poverty, 359
somatic, 359

Demand ischemia, 416
Dementia, 284–295
agression or agitation in, 304
alcohol-related, 372
of Alzheimer disease, 101
assessment of, 285–286
associated with Parkinson disease, 529
behavioral interventions for, 298–299, 299t
behavioral problems in, 296–304
CAM for, 101
definition of, 287
delirium and, 308
delusions in, 301–303, 302r
depression in, 296–297, 299–300, 300t
diagnostic features of, 287, 289
differential diagnosis of, 285–287
differentiating types of, 287–289
end-stage, 146
epidemiology of, 284
ethical issues in, 35–36
etiology of, 284–285
frontotemporal, 284–285, 288, 288t
general progression of, 289, 290t
hallucinations in, 301–303, 302r
in hospitalized patients, 146
and urinary incontinence, 245
and poverty, 285
Lewy body, 284–285, 288, 288t, 360–361, 530t
management of, 289–294
manic-like behavioral syndromes in, 300–301
with mental retardation, 380–381
Mini-Cog Assessment Instrument for
Dementia, 55, 83, 145, 286, 287t
mixed, 284
mood disturbances in, 299–300
in nursing-home population, 166–167
pharmacologic treatment of, 292–294
prevention of, 78–79r, 285
protective factors for, 285, 285t
psychosis in, 301–303, 302t, 359–360
pugilistic, 380
and rehabilitation, 157
resources for, 294
reversible, 305
risk factors for, 285, 285t
safety concerns, 291–292
screening for, 83
sleep disturbances in, 303, 320–321
societal impact of, 284
supportive therapy for, 289
treatment of, 287, 288t, 299–294
and urinary incontinence, 245
vascular, 284, 287–288, 288t
Dementia caregiver counseling, 349, 350
Demography
of aging, 2–8
Demography of aging, 2–8
Depression, 340–351
clinical presentation of, 340–343
management of, 289–294
Depression care management, 349
Depression care management, 349
Depressive personality disorder
features of, 362, 363t
therapeutic strategies for, 365, 365t
Depression, 340–351
activity recommendations for, 71t
bipolar, 345–349
CAM for, 101
in chronic kidney disease, 469
clinical presentation of, 340–343
in dementia, 296–297, 299–300
with developmental disabilities,
382–384, 383t
Diagnosis of, 340–343
electroconvulsive therapy for, 344–345, 349–350
epidemiology of, 340
Geriatric Depression Scale, 55, 342, 342t
in hospitalized patients, 143t, 145
indications to start antidepressant therapy based on PHQ-9, 341–342, 342t
interventions for, 143t, 145
interventions for preventing falls, 268
late-life, geriatric syndrome of, 340–341
major depressive disorder without mania but with hypomania, 343
mania with or without, 343
with marked anxiety, 354
minor, 340, 343–344
in nursing-home population, 167
pharmacotherapy for, 299–300, 300t, 344–345
prescriber response guidelines based on PHQ-9 and the STAR*D studies for, 342, 342t
psychosocial interventions for, 350–351
psychotherapy for, 349t, 350–351
psychotic, 343
rapid screening followed by assessment and management of, 52, 53
recommended preventive measures for, 79t
and rehabilitation, 156–157
remission of, 342
with severe anxiety, 355, 355t
subclinical, 343–344
subsyndromal, 340, 343–344
in terminal illness, 124–125
terminal, 343–351
Depression care management, 349, 350
Depression screening, 79, 83, 341–342
Depressive personality disorder
features of, 362, 363t
therapeutic strategies for, 365, 365t
Dermatitis
neurodermatitis, 383
seborrheic, 387, 387t
stasis dermatitis, 391–392
Dermatoфibromas, 520
Dermatologic diseases and disorders, 386–398
skin and nail disorders of foot, 519–521

Geriatric Review Syllabus, 8th Edition
610
skin cancer, 396–397
skin infections, 539–540, 541t
Dermatomyositis, 505–506
Desipramine (Norpramin)
for depression, 346t
for depressive features of behavioral disturbances in dementia, 299–300, 300t
for persistent pain, 135t
Desvenlafaxine, 300, 300t
DETERMINE checklist, 236
Detoxification, 373, 374–376, 375t
Detrusor hyperactivity with impaired contractility (DHIC), 244
Diteassist (salsalate), 136
Diallylamine
adverse drug events, 92, 92t, 235
drug interactions, 93, 93t
for heart failure, 436–437
nutrient interactions, 235, 235t
Dihydropyridines, 235
Dilation (hydromorphone), 136t
Diltiazem
adverse drug events, 92, 92t
for atrial fibrillation, 426
Dilutional hypotension, 462
Diogenes syndrome, 354
Diphenhydramine
adverse drug events, 92, 92t
for delirium, 311t
for nausea, 124t
Dipiverin, 210t
Diplopia, 202, 204t
Disability
excess, 371–372
International Classification of Functioning, Disability, and Health (ICF) (WHO), 152
preclinical, 53
trends in, 5–6
Disability accommodation, 6–7
Disabled dual eligibles, 42
Disacide (salsalate), 136t
Discharge destinations, 179
Discharge medication regimen, 179
Disclosure, 66
Discontinuing interventions, 32–33
DISCUS (Dyskinesia Identification System Condensed User Scale), 358–359
Disease management, 191–192
Disease-modifying anti-inflammatory drugs (DMARDs), 502
Disengagement theory, 10
Dislocation
of lesser metatarsal phalangeal joint, 515t
of metatarsal phalangeal joint, 517, 518t
Disorganized thinking, 306, 307t
Disseminated intravascular coagulation, 583
Disulfiram, 374–376, 375t
Diuretics
adverse drug events, 92, 92t
drug interactions, 93, 93t
for heart failure, 436

for hypertension, 443
loop, 245, 436
nutrient interactions, 235, 235
thiazide-type, 443
Divalproex sodium
for behavioral disturbances in
dementia with manic-like
features, 301, 301
for personality disorders, 366
to stabilize mood in mania and
bipolar depression, 345, 348
Diverticular disease, 455
Dix-Hallpike test, 224, 257
Dizziness, 221–226
classification of, 221–223, 223
diagnostic testing for, 225
evaluation of, 223–225
history, 223
management of, 225
mixed, 221, 223
physical examination of, 223–224
prevalence of, 221
DMARDs (disease-modifying anti-
inflammatory drugs), 302
DO (detrusor overactivity), 245–246
“Do-not-hospitalize” orders, 175
Do-not-resuscitate (“DNR”) bracelets, 31
Docetaxel, 591, 596
Docusate (Colace), 453
Donepezil, 293, 361
Doorway thoughts in cross-cultural health
care, 62
Dopamine agonists
and delirium, 311
for Parkinson disease, 529
for periodic limb movement disorder,
320
for restless legs syndrome, 320
Dopamine antagonists, 124
Dorzolamide, 210
Double crush phenomenon, 497–498
Double effect, rule of, 33
Down syndrome, 378–379, 380–381
Doxepin
and delirium, 311
for insomnia, 324, 325
Doxycline, 548
DPP-4 enzyme inhibitors, 571, 572
Dramatic, emotional, or erratic behaviors,
362, 363
Dressings for pressure ulcers, 332–333,
335
DRGs (diagnostic-related groups), 182
Drinking, See Alcohol
DRIs (dietary reference intakes), 233–234
Driving
ethical issues, 35
risk factors for automobile accidents,
56
Driving assessment, 56–57
recommendations for, 79, 84
Dronabinol, 238
Dronedarone, 426
Drug abuse. See also Substance abuse
magnitude of the problem, 370
Drug-drug interactions (DDIs), 93, 93
Drug holidays, 280
Drug-induced esophageal injury, 449–450
Drug-induced movement disorders,
531–532
Drug-nutrient interactions, 235, 235
Drug regimen review, 95
Drugs. See also Pharmacotherapy; specific
drugs
absorption of, 87–88
adverse drug events, 92, 92, 355
for anxiety disorders, 355–356, 355
to avoid in older adults, 138
in chronic kidney disease, 468
clearance of, 88–89
for depressive features of behavioral
disturbances in dementia, 299, 300
 discontinuing, 94–95
distribution of, 88
elimination of, 88–89
guidelines for prevention of falls, 266
half-life of, 88–89
health insurance coverage for, 40
hydrophilic, 88
inappropriate/overprescribed and
underprescribed medications/
classes, 90, 90, 91
for incontinence, 250–251
interventions for preventing falls,
260
lipophilic, 88
Medicare Prescription Drug Plan
Finder (CMS), 41
metabolism of, 88
nonadherence to regimens, 95
outpatient, 40
outpatient care, 40
to reduce or eliminate in management
of delirium, 309–310, 311
requirements for long-term care
facilities, 172, 173
sleeping medications, 321
to stabilize mood in mania and
bipolar depression, 348
Driving assessment, 56–57
ethical issues, 35
risk factors for automobile accidents,
56
recommendations for, 70–72, 71t
to reduce risk of osteoporosis, 274, 274t
relative exercise intensity, 69
for sleep problems, 323
vestibular rehabilitation therapy (VRT), 225
Exerc. A Guide from the Ntl Institute on Aging, 74
Exercise intensity, 69, 70t
Exercise is Medicine Initiative (ACSM), 73
Exercise Management for Chronic Diseases and Disabilities (ACSM), 73
Exercise volume, 69, 70t
Extraction, 105, 106t
Extended-care settings, 34–35
External beam radiation therapy, 484t
Extracellular fluid volume contracted, 461–462
expanded, 462
normal, 462
eye conditions, 202–205, 203t, 204t
Eye drops, 209–210, 210t
Eye conditions, 202–205, 203t
Eye drops, 209–210, 210t
Eyes
age-related changes, 14t, 16
age-related pathologies, 18t
comprehensive examination of, 202
F
F-tags, 170, 251, 252
FACES Pain Rating Scale with Foreign Translations, 129
Faces Pain Scale, 129, 130f, 337
Facial nerve palsy (Bell’s palsy), 548
Facial volume restoration, 386–387
Factor VIII, 585
Facial nerve palsy (Bell’s palsy), 548
Fearful behaviors, 362, 363t
Fecal impaction, 452
Fecal incontinence, 454
with developmental disabilities, 382–384, 383t
Fecal occult blood testing, 456
recommendations for, 77–80, 78t
Federal Coordinated Health Care Office, 42–43
Federal financing of health care, 48–50
Fee-for-service (FFS) care
discounted FFS, 45
home-health care, 47
inpatient care, 45
Medicare, 37, 38–39, 40t, 44, 44t
Medicare Advantage, 45, 45t
nursing-home care, 47
outpatient care, 43–44
postacute rehabilitation, 46
private plans, 40
Feeding, 241–243
artificial, 239
hand, 241
tube, 241, 242
Feeding problems, 240–243
Feeding tubes, 239, 241, 242
Female sexual dysfunction, 488–489
evaluation of, 489
treatment options for, 489, 490t
Female sexuality, 488
Fentanyl, transdermal (Duragesic), 137t
Fesoterodine, 250
Festination, 255t, 528
Fever
antibiotic therapy for, 539–540, 541t
evaluation of, 548t, 549
in frail, older residents of long-term care facilities, 539–540, 540t
in older nursing-home residents, 539–540
of unknown origin, 548t, 549
FFS care, See Fee-for-service care
Fiber, 452, 452t
FiberCon (polycarbophil), 453t
Fibrinolitic therapy, 420
Fibromyalgia, 129, 498–499
FIM (Functional Independence Measure), 153–154, 155t
Financial assessment, 106
Financial mistreatment, 106
Financing
for assisted living, 187
costs of hearing aids, 217–218, 218t, 219
end-of-life care, 48
federal, 48–50
health care, 37–50
home-health care, 47
for house calls, 184
inpatient care, 45–46
nursing-home care, 47
for nursing-home care, 168
outpatient care, 43–45
personal, 29, 30t
postacute rehabilitation, 46
for rehabilitation services, 152–153, 153t
Fine-needle aspiration (FNA), 554
Firearms, 35
Fitness, low, 74
“Five A’s” for smoking cessation, 376
Five Wishes, 31, 31t
Flushes, 204t
Flat foot, 516
Flavor enhancement, 405
Flavoxate, 250
Fleet (sodium phosphate/biphosphate emollient enema), 453t
Flexibility activity recommendations, 71, 71t
Flexible sigmoidoscopy, 77
Floaters, 202, 204t
Flu shots, 78t
Flucconazole, 93, 93t
Fludarabine, 591
Fludarabine, 519
Fluid needs, 234
Flucoxetine, 250
for depression, 346t
for depressive features of behavioral disturbances in dementia, 299, 300t
to stabilize mood in mania and bipolar depression, 348t
Flurazepam, 311t
Fluticasone, 412t
FNA (fine-needle aspiration), 554
Focal segmental glomerulosclerosis, 464

614 Geriatric Review Syllabus, 8th Edition
Folate
  drug interactions, 235, 235t
  RDIs for adults ≥ 71 years old, 234t
Folate deficiency, 581, 581t
Folic acid, 237
Folic acid replacement, 583
Follicular lymphoma, 597
Folstein Mini–Mental State Examination (MMSE), 29–30, 55, 83, 145, 286, 287t
Fondaparinux, 419, 431–432
Food and Nutrition Board, Institute of Medicine, 233–234
Foods, calcium-containing, 278, 278t
  for prevention of falls, 267
  in diabetes mellitus, 570
  guidelines for prevention of falls, 267
  skin and nail disorders, 519–521
  surgical considerations for deformities, 519
  systemic diseases, 521–522
Foot care, 514
Foot diseases and disorders, 514–522, 515t
  associated deformities, 516–518
  in diabetes mellitus, 570
  guidelines for prevention of falls, 267
  skin and nail disorders, 519–521
  surgical considerations for deformities, 519
  systemic diseases, 521–522
  treatment strategies for, 518–519
Foot drop, 255–256, 255t
Foot examination, 570
Foot slap, 255
Footwear
  for preventing falls, 267
  shoe terms, 519t
  shoes, 519
Forgoing and discontinuing interventions, 32–33
Formality, 63
Formoterol fumarate, 412t
Fortamet (metformin), 572
Foster care, 188
Fosinopril, 435
Free radical theory of aging, 11t, 12
Freezing of gait, 254
Festinating, 255
Festinatory, 255
Festinating, 255
Festinating, 255
Festinating, 255
Festinating, 255
Free water deficit, 463
Freezing of gait, 254t, 528
Frontotemporal dementia
diagnostic features and treatment of, 258t
FRAX™ (fracture risk assessment model)
  (WHO), 271, 273t, 274
  etiology of, 284–285
Frozen shoulder, 497
Fukuda stepping test, 224
Functional Activities Questionnaire, 286
Functional Ambulation Classification scale, 258
Functional Independence Measure (FIM), 153–154, 155t
Functional reach test, 265
Functional status
  acute decline, 57
  assessment of, 53–54, 154t
  with developmental disabilities, 382–384, 383t
  impairments in hospitalized patients, 143t, 144
International Classification of Functioning, Disability, and Health (ICF) (WHO), 152
Interventions for, 143t
Interventions for, 143t
Interventions for, 143t
Interventions for, 143t
Interventions for, 143t
low fitness or low functional ability, 74
  of nursing-home population, 166, 167t
  performance-based assessment of, 257–258
  rapid screening followed by assessment and management of, 52, 53t
trends in, 4–5
Fungal infections, 520–521, 520t
FUO (fever of unknown origin), 548, 549
Furosemide, 235
Futility, 149
Future issues, 7–8

G
GABAergic agents, 245t
Gabapentin (Neurontin, Gralise)
  for epilepsy, 334t
  and incontinence, 245t
  for persistent pain, 135t, 138
  for restless legs syndrome, 320
  for vasomotor symptoms, 473
Gait abnormalities, 255–256, 255t, 256t
  antalgic gait, 255–256, 255t, 256t
  festinating, 255t, 528
  freezing, 254t, 528
  steppe gait, 255t, 256t
  Trendelenburg gait, 255–256, 255t, 256t
Gait and balance screening, 79t
Gait apraxia, 257
Gait impairment, 54, 254–260
  assessment of, 255–258
  associated findings, 256t
  conditions that contribute to, 254–255
  epidemiology of, 254
  history and physical examination of, 257
  interventions for preventing falls, 268t
  interventions to reduce disorders, 258–260
  laboratory and imaging assessments of, 257
  performance-based functional assessment of, 257–258
Gait speed, 54, 258
Gait training, 268t
Galantamine, 293, 381
Gallstones, 451
Gambling, 376
Gammopathy, monoclonal, of uncertain significance, 597–598
Gastroesophageal reflux disease, 448–449
Gastrointestinal bleeding, 456
Gastrointestinal diseases and disorders, 447–459
with developmental disabilities, 382–384, 383t
and incontinence, 246t
infections, 548
Gastrointestinal system, 115–116
Gastroscopy
contraindications to, 242
percutaneous endoscopic, 242
Gastroscopy tube placement, 242
GEM (geriatric evaluation and management) units, 149, 190
Gemicitabine, 591
Gender differences
cultural aspects, 66
in drug metabolism, 88
in urinary incontinence, 245
Generalized anxiety disorder, 354, 355, 355t
Genetic damage, 10, 11t
Genu recurvatum, 255
GEO (geographical practices cost indices), 448–449
Geriatric Depression Scale, 55, 83, 342, 342t
Geriatric evaluation and management (GEM) units, 149, 190
Geriatric Resource Nurse (GRN) Model, 150
Geriatric Resources for Assessment and Care of Elders (GRACE), 190–191
Geriatric specialty care, 189
Geriatric syndrome of late-life depression.
See Depression
Geriatrics-orthopedics services, 313
Gerotranscendence theory, 10
GFR. See Glomerular filtration rate
Giant cell arteritis, 504
t head due to, 527
signs and symptoms of, 202, 204t
Ginkgo biloba, 101
for dementia, 293
safety issues, 98, 99t
Glaucoma, 209–210
angle-closure, 202, 203, 204t
definition of, 209
eye drops for, 209–210, 210t
narrow-angle, 203t
open-angle, 203t, 209–210
screening for, 84
symptoms and treatment of, 203t
types of, 209
Gleason grading system, 483
Glimepiride (Amaryl)
for diabetes mellitus, 572t
pioglitazone and glimepiride (Duetact), 573t
rosiglitazone and glimepiride (Avandaryl), 573t
Glipizide (Glucotrol, Glucotrol XL), 572t
Glipizide and metformin (METAGLIP), 573t
Global aging trends, 2
Global Initiative for Chronic Obstructive Lung Disease (GOLD), 410–411, 411t
Glomerular filtration rate (GFR), 111–113
age-related changes in, 89, 461t
estimating (eGFR), 89
Glomerulonephritis
acute, 466–467
membranoproliferative, 464
mesangial, 464
Glomerulosclerosis, focal segmental, 464
Glucocorticoid hypersecretion, subclinical, 559
Glucocorticoids
adverse drug events, 92, 92t
and bone loss, 275
for dermatomyositis, 506
for giant cell arteritis, 504
for knee pain, 501
for musculoskeletal pain, 500
for polymyositis, 506
Glucophage (metformin), 572t
Glucophage XR (metformin), 572t
Glucosamine, 98, 99, 99t
Glucose intolerance, 567
Glucose screening, 78t
α-Glucosidase inhibitors, 571, 572t
Glucotrol (glipizide), 572t
Glucotrol XL (glipizide), 572t
Glucovance (glyburide and metformin), 573t
Glumetza (metformin), 572t
Glyburide (Diaβeta, Micronase)
for diabetes mellitus, 572t
micronized (Glynase), 572t
Glyburide and metformin (Glucovance), 573t
Glycemic control, 570–571
Glycoprotein IIb/IIa inhibitors, 419
Glycopyrrolate
for bowel obstruction, 125t
for loud respirations, 126
Glyset (miglitol), 572t
Gout, 502–503
GRACE (Geriatric Resources for Assessment and Care of Elders), 190–191
Grading of Recommendations Assessment, Development and Evaluation working group (GRADE), 60
Gralise (gabapentin), 135t
Grand mal seizures, 532
Granisetron, 124t
Granulocyte colony-stimulating factor, 592t
Granulocyte-macrophage colony-stimulating factor, 592t
Green House Model, 174
Green Prescription (New Zealand), 73
Grief, 22
Grief therapy, 349t, 350
Group exercise, 259–260
Group homes, 187–188
Growth factors, 327, 336
Growth hormone, 238, 563–564
Growth hormone deficiency, 563–564
Growth retardation, 382–384, 383t
Guidians, 31
Guided Care, 191
Gustatory dysfunction
medications that cause, 405, 406t
nonpharmacologic causes of, 405, 406t
Gynecologic diseases and disorders, 472–478

H
H1N1 pandemic, 543
H2-receptor antagonists
adverse drug events, 235
and delirium, 309–310, 311t
for nausea, 124t
HAART (highly active antiretroviral therapy), 547
Haemophilus influenzae, 542
Haglund deformity, 515t
Hairy tongue, 405, 406t
Half-life, 88
Hallucinations
antipsychotic medications for, 301–303, 302t
definition of, 357
in dementia, 301–303, 302t
in dementia associated with Lewy bodies, 360
evaluation of patient with, 357
isolated, 360–361
Hallus valgus, 517
Hallux abducto valgus, 515, 518
Hallux limitus, 515, 517
Hallux rigidus, 515
Hallux valgus, 515
Haloperidol
for agitated delirium, 312–313, 312
for psychosis in dementia, 302
for nausea, 124
for psychosis in dementia, 302
Hammer toe, 515
517
Hallux limitus, 515, 517
Hand feeding, 241
Hand osteoarthritis, 500–501
Handoffs, 177
Hand osteoarthritis, 500–501/
Handovers, 177
Harpagophytum procumbens (devil’s claw), 100
Harris Hip Questionnaire, 154
Hayflick’s limit, 11
Head-thrust test, 224
Heart failure
See HF.
Heart failure
Cheynes-Stokes breathing pattern of, 318
Cheynes-Stokes breathing pattern of, 318
classification of, 436, 436
clinical features of, 433–434
device therapy for, 437–438
diagnosis of, 434
diastolic, 437
end-of-life care for, 439
epidemiology of, 433
etiology of, 433
and incontinence, 246
management of, 434–438
pathophysiology of, 433
prognosis, 439
recurrent hospitalization for, 438–439
systolic, 437
Heart rate abnormalities, 267
Heat therapy, 499
Heavy drinking, 370
HEPIS (Healthcare Employers’ Data Information System), 48–49
Heel pain, 518
Heel pressure ulcers, 331, 331
Heel spur, 515
Height measurement, 78, 84
Helicobacter pylori infection, 450
HELP (Hospital Elder Life Program), 150, 313
HELP (Hospitalized Elderly Longitudinal Project), 119
Hemangioma, 520
Hematochezia, 520
Hematoma, subdural, 526
Hematopoiesis, 576–577
Hematopoietic stem cells, 576
Hemodialysis, 469–470
Hemoglobin, replacement, 468
Hemolytic anemia, 576–586
Hemorrhage
intracerebral, 526
subconjunctival, 203–204, 204
Hepatitis A vaccine, 539, 540
Hepatitis B vaccine, 539, 540
Hepatitis C virus, 539, 540
Herbal medicine, 97–98
Herpes simplex, 404–405
Herpes simplex keratitis, 203, 204
Herpes zoster (“shingles”), 204, 205, 392–393, 393
Herpes zoster ophthalmicus, 205
Herpes zoster vaccine
immunization schedule for adults ≥65
years old, 539, 540
recommendations for, 78, 85
HF. See Heart failure
HHRGs (home-health-related groups), 182
HHS (U.S. Department of Health and Human Services), 71, 72
Index 617
High T4 syndrome, 552
Highly active antiretroviral therapy (HAART), 547
Hip fracture, 159–160
  epidemiology of, 159–160
  prevention of recurrence, 160
  rehabilitation after, 160
  surgical care of, 159–160
Hip joint assessment, 154t, 158, 160
Hip pain, 498
  158, 160
Hip joint assessment, 154
surgical care of, 159–160
rehabilitation after, 160
prevention of recurrence, 160
epidemiology of, 159–160
Hip fracture, 159–160
Highly active antiretroviral therapy codes, reimbursement, and
Home care, 182–185
Hodgkin disease, 589, 597
Hmong, 23
HIV screening, 78t, 82
HIV infection, 168, 547
HIV screening, 78t, 82
Hmong
Hodgkin disease, 589, 597
Home care, 182–185
codes, reimbursement, and
requirements for certification, 183, 183t
ethical issues in, 185
falls risk in, 263t
fee-for-service, 47
financing, 47
health insurance coverage for, 40t
liability and legal issues, 185
limitations of, 185
managed care, 47
patient assessment, 183
physician’s role in, 182–183
preventing falls, 267, 269t
prospective payment system for, 182
rehabilitation services, 153t, 154–155
  technologic innovations in, 187
Home-delivered meals, 237
Home-health–related groups (HHRGs), 182
Home hospital, 150–151, 186–187
Home safety evaluation, 267, 269t
Homeostasis, 18–19, 327
Homocysteine, 583
Hormonal regulation
  influences in men, 273–274
  screening tests for hypersecretion, 559, 560t
  of water and electrolyte balance, 558
Hormone therapy
  for breast cancer, 591, 596
  for cancer, 591
  for endometrial cancer, 591
  for erectile dysfunction, 494
  estrogen therapy, 563
  for female sexual dysfunction, 489, 560
  growth hormone supplementation, 563–564
  for incontinence, 245t, 250
  for menopausal symptoms, 473
  for osteoporosis, 279, 280–281
  preventive, 79t, 85
  for prostate cancer, 591
  testosterone replacement therapy, 560–561
  testosterone supplementation, 561–562, 562t, 563t
  for urogenital atrophy, 473–474
Horn syndrome, 525
Hospice, 120
cultural aspects, 23, 119
for end-stage kidney disease, 470–471
health insurance coverage for, 40t
services, 120, 121t
Hospital-acquired pneumonia, 542–543
Hospital-acquired pressure ulcers
  incidence of, 147
  prevention of, 143t, 147
Hospital-at-home care, 150–151
Hospital care, 142–151
  alternatives to, 150–151
  daily evaluation, 149
  day hospitals, 185–186
  falls risk in, 263t
  geriatric evaluation and management (GEM) units, 149, 190
  hazards and opportunities commonly overlooked in, 143–144, 143t
  health insurance coverage for, 40t
  home hospitals, 186–187
  recurrent, 438–439
rehabilitation hospitals, 153–154, 153t
  systematic assessment on admission, 143, 143t
Hospital Elder Life Program (HELP), 150, 313
Hospitalization, chronic, 179
Hospitalized Elderly Longitudinal Project (HELP), 119
Hospitalized patients
  assessment of, 142–149
  daily evaluation, 149
  management of, 142–149
  sleep disturbances in, 321
  systems of care for, 149–150
Hot flushes, 473
House calls, 183
  billing codes and reimbursement for, 184, 184t
  choosing patients for, 184
  financial considerations, 184
  office-based programs, 183–184
Housing and Urban Development programs, 188
HSDD (hypoactive sexual desire disorder), 489
Humalog (insulin lispro), 574t
Human growth hormone, 238
Human immunodeficiency virus (HIV) infection, 168, 547
Humulin (insulin), 574t
Huntington disease, 531
Hurley Discomfort Scale, 131
Hutchinson sign, 205, 393
Hwabyeong, 367
Hydralazine, 437, 444
Hydrocephalus, normal-pressure (NPH) and incontinence, 246t
surgery for, 259
Hydrochlorothiazide, 443
Hydrocodeone (Lorcet, Lortab, Vicodin, Norco, Vicoprofen), 136t
Hydrocortisone, 117
Hydrocortisone
Hydrocodone (Lorcet, Lortab, Vicodin, Norco, Vicoprofen), 136t
Hydrochlorothiazide, 443
Hydrocodeone (Lorcet, Lortab, Vicodin, Norco, Vicoprofen), 136t
Hydrocortisone, 117
Hydrocortisone
Extended release (Exalgo), 136t
Hydrophilic drugs, 88
Hydrophilic drugs, 88
Hydroxychloroquine, 505
Hydroxyurea, 585, 586
Hydroxyurea, 585, 586
Hydroxycarbamide, 585, 586
Hydroxocaine, 250
for bowel obstruction, 125t
for loud respirations, 126
Hyperadrenocorticoidism, 559
Hyperalgesia, 130t
Hypercalcemia, 556–557
differential diagnosis of, 556, 557t
and incontinence, 246t
Hypercalciuria, idiopathic, 274
Hyperglycemia
in diabetes mellitus, 574–575
management of, 570–574
perioperative, 116
Hypericum perforatum (St. John’s wort),
for depression, 346t
safety issues, 98, 99t
Hyperkalemia, 463
Hyperkinetic movement disorders, 531
Hyperlipidemia, 81–82
Hypernatremia, 462–463
Hyperparathyroidism, 556, 557t
screening for secondary osteoporosis
in, 274–275, 275t
secondary, 273
Hyperpathia, 130t
Hypersexualtivity, 303–304
Hypertension, 440–446
CAM for, 100–101
and cardiovascular risk, 417
classification of, 440, 440t
clinical evaluation of, 441
emergencies and urgencies, 445
epidemiology and physiology of, 440–441
follow-up visits, 444–445, 444t
in long-term care setting, 445
pharmacologic treatment of, 442–444
prehypertension, 440, 440t
prevalence of, 4, 5f
recommended preventive measures
for, 78t
screening for, 81
special considerations for, 445
stage 1, 440t
stage 2, 440t
treatment of, 441–445, 443t
white-coat, 441
Hyperthyroidism, 552–553
subclinical, 553
Hypertonict saline, 462
Hypnotictcs
chronic use of, 324–325
and delirium, 311t
and incontinence, 245t
interventions for preventing falls
with, 266t
for sleep problems, 321
Hypoactive sexual desire disorder (HSDD),
489
Hyperadrenocorticoidism, 559
Hypoaldosterontism, hyporeninemic, 558
Hypoalgesia, 130t
Hypochondriasis, 366
Hypoglycemia, 574–575
Hypogonadism, 273–274
male, 491–492, 491t
screening for secondary osteoporosis
in, 275, 275t
testosterone preparations available
for, 561–562, 562t
Hypokalemia, 463
Hypomania, 343
Hypoplastic anemia, 578–579, 580f
due to iron deficiency, 578–579, 580f
due to vitamin B12 or folate
deficiency, 581, 581f
Hyporeninemic hypoaldosteronism, age-
related, 558
Hypotension, postural, 231, 267, 268t
Hypothyroidism, 551–552
secondary, 551–552
subclinical, 551
Hypotonic hyponatremia, 461–462
IADLs. See Instrumental activities of daily
living
Ibandronate, 279t, 290
IBS (irritable bowel syndrome), 452,
455–456
Ibuprofen
for musculoskeletal pain, 500
for persistent pain, 133, 136t
ICD-9 (International Classification of
Diseases), 182
ICDs (implantable cardiac defibrillators),
437–438
Implantable loop recorders (ILRs),
230–231
Implants, cochlear, 219–220
characteristics of older candidates
for, 219–220, 219t
Improving Mood—Promoting Access to
Collaborative Treatment (IMPACT),
191–192
Immunizations, 78t, 84–85
for hospitalized patients, 143t, 148
recommendations for, 84–85
schedule for adults ≥65 years old,
539, 540t
Immunosenescence, 538
Inattention, 306, 307t
Incontinence
with developmental disabilities,
382–384, 383t
fcal, 454
and rehabilitation, 156
urinary, 79t, 83, 102, 244–253
Ineffective anemia, 578, 579t
Ineffective erythropoiesis, 581–582
Infections
antimicrobial management of, 540–
541
bone and joint, 546–547
diagnosis and management of, 539–
541
fungal, 520–521, 520f
gastrointestinal, 548
HIV and AIDS, 547
predisposition to, 538–539
presentation of, 539–540
in pressure ulcers, 336–337
prevention of, 541
prosthetic device infections, 546
sexually transmitted, 82
skin problems, 392–394
vulvovaginal, 474
Infectious diarrhea, 548–549
Infectious diseases, 538–549
Infectious Diseases Society of America, 542
Infectious syndromes, 541–549
Infective endocarditis, 545–546
Infestation, 392–394
Infectious endocarditis, 545–546
infected, 4–5, 6
Inflammation
anemia of, 579
vulvovaginal, 474
Inflammatory cytokines, 238
Inflammatory skin conditions, 387–392
vulvovaginal, 474
anemia of, 579
Inflammation
Infidelity, 359–360
Infestations, 392–394
Infective endocarditis, 545–546
Infectious syndromes, 541–549
Infectious endocarditis, 545–546
Infestation, 392–394
Inflammation
Influenza, 543
deaths due to, 4–5, 6t
influenza vaccine, 410–411
immunization schedule for adults ≥65
years old, 539, 540t
recommended immunizations for, 78t,
84–85
influenza vaccine, 410–411
vaccination against, 78t, 84–85, 148
Information
guidelines for prevention of falls, 267
medical director responsibilities for,
171t, 172–173
Information
inguidelines for prevention of falls, 267
medical director responsibilities for,
171t, 172–173
Informed consent for research, 32
Infusion therapy
Injectable agents, 573
Inhalers, 411
Inhaled bronchodilators, 411, 412t
INH (isoniazid), 545
to prevent, 364
Influenza, 543
deaths due to, 4–5, 6t
influenza vaccine, 410–411
immunization schedule for adults ≥65
years old, 539, 540t
recommended immunizations for, 78t,
84–85
influenza vaccine, 410–411
vaccination against, 78t, 84–85, 148
Injury
deaths due to unintentional injuries,
4–5, 6t
preventing, 84
Inpatient care
fee for service, 45
financing, 45–46
managed care, 46
rehabilitation care, 155
Insomnia, 317–318
behavioral management of, 303, 303t
behavioral treatment of, 322
epidemiology of, 316
nonpharmacologic interventions for,
323
prescription medications for, 323–
324, 325t
prevalence of, 317
Institute for Healthcare Improvement, 329
Institute of Medicine Food and Nutrition
Board, 233–234
Institutional mistreatment, 107
Institutionalization decisions, 185
Instrumental activities of daily living
(IADLs), 53, 54t, 144
self-reported limitations, 6
Insulin
for diabetes, 571–574
preparations, 571–574, 574t
Insulin aspart (NovoLog), 574t
Insulin aspart protamine and insulin aspart
(NovoLog Mix 70/30), 574t
Insulin detemir (Levenir), 574t
Insulin glargine (Lantus), 574t
Insulin glulisine (Apidra), 574t
Insulin glargine (Lantus), 574t
Insulin, 234
insulin-like growth factor 1, 238
Insulin detemir (Levenir), 574
Insulin glargine (Lantus), 574
Insulin glulisine (Apidra), 574
Insulin aspart protamine and insulin aspart
(NovoLog Mix 70/30), 574t
Insulin aspart (NovoLog), 574t
Insulin aspart protamine and insulin aspart
(NovoLog Mix 70/30), 574t
Insulin detemir (Levenir), 574t
Insulin glargine (Lantus), 574t
Insulin glulisine (Apidra), 574t
Insulin-like growth factor 1, 238t
Insulin lispro (Humalog), 574t
Intensive care
Confusion Assessment Method for the
Intensive Care Unit (CAM-ICU),
306, 307t
of critically ill, 148–149
Interferon, 583–586, 592
Interleukin-2, 592
Interleukin-6, 577
Intermittent clean catheterization, 252
Internal carotid artery disease, 524–525
International Classification of Diseases
(ICD-9), 182
International Classification of Functioning,
Disability, and Health (ICF) (WHO),
152
International Continence Society, 475
International Society of Clinical
densitometry, 276
Interpreters, 63–64
Interventional nephrology, 526
Interventional radiology, 526
Investigational agents, 282
Ipratropium bromide
adverse drug events, 235
for COPD, 411, 412t
Irbesartan, 435t
Iron, 234t
Iron-containing antacids, 92, 92t
Iron deficiency, 468, 578–579, 580t
Iron therapy
for anemia, 579
for restless legs syndrome, 320
Irritable bowel syndrome, 452, 455–456
Ischemic optic neuropathy, 202, 204t
Ischemic stroke
acute, 525–526
prevention of, 524–525
Isolavones, 102
Isoniazid (INH), 235, 235t, 545
Isosorbide dinitrate, 437
Isosorbide mononitrate, 422
Ivermectin, 394
Jaeger cards, 54, 145
Janumet (sitagliptin and metformin), 573t
Januvia (sitagliptin), 572t
Japanese Americans, 166
Jehovah’s Witness, 28
Jejunostomy, percutaneous endoscopic, 242
Jentadueto (linagliptin and metformin),
573t
Joint disease, degenerative, 382–384, 383t
Joint infections, 546–547
Joint Principles of the PCMH (AAP , ACP,
AAFP, AOA), 190
Joint replacement
knee replacement, 259
total hip and knee arthroplasty, 160–
161
Judgment, substituted, 28, 30–31, 30t
Justice, 28–29
Kadian (morphine, sustained release), 136t
Kava, 326
KDOQI (Kidney Disease Outcomes
Quality Initiative), 89
Keratitis, bacterial, 202, 204t
Keratitis sicca, 203–204
Keratotic lesions, 519
Ketoconazole, 250
Ketoconazole, 250
Kadian (morphine, sustained release), 136t
Kava, 326
KDOQI (Kidney Disease Outcomes
Quality Initiative), 89
Keratitis, bacterial, 202, 204t
Keratitis sicca, 203–204
Keratotic lesions, 519
Ketoconazole, 250
Ketorolac, 136t
Kidney(s)
acute kidney injury, 465–467
chronic kidney disease, 467–469
end-stage kidney disease, 469–471
impaired kidney function, 89
intrinsic renal disease, 466–467
524–525
prevention of, 524–525
Isolavones, 102
Isoniazid (INH), 235, 235t, 545
Isosorbide dinitrate, 437
Isosorbide mononitrate, 422
Ivermectin, 394
Jaeger cards, 54, 145
Janumet (sitagliptin and metformin), 573t
Januvia (sitagliptin), 572t
Japanese Americans, 166
Jehovah’s Witness, 28
Jejunostomy, percutaneous endoscopic, 242
Jentadueto (linagliptin and metformin), 573t
Joint disease, degenerative, 382–384, 383t
Joint infections, 546–547
Joint Principles of the PCMH (AAP, ACP,
AAFP, AOA), 190
Joint replacement
knee replacement, 259
total hip and knee arthroplasty, 160–
161
Judgment, substituted, 28, 30–31, 30t
Justice, 28–29
Kadian (morphine, sustained release), 136t
Kava, 326
KDOQI (Kidney Disease Outcomes
Quality Initiative), 89
Keratitis, bacterial, 202, 204t
Keratitis sicca, 203–204
Keratotic lesions, 519
Ketoconazole, 250
Ketorolac, 136t
Kidney(s)
acute kidney injury, 465–467
chronic kidney disease, 467–469
end-stage kidney disease, 469–471
impaired kidney function, 89
intrinsic renal disease, 466–467
Modified Diet in Renal Disease (MDRD) formula, 89, 111–113, 460
monitoring, 460
postoperative management of, 115
renal function impairment, 89
Kidney transplantation, 470
Klebsiella, 542
Klonopin (clonazepam), 135
Knee osteoarthritis, 500–501, 501f
Knee pain, 498
Knee replacement rehabilitation after, 259
total hip and knee arthroplasty, 160–161
Kombiglyze XR (saxagliptin and metformin), 573
Korean Americans, 166
Kyphoplasty, 283
L
Labetalol, 444
Labor force participation, 3–4, 22–23
Laboratory testing, 235
in anemia, 578, 580f, 581f
in falls, 266
in gait impairment, 257
health insurance coverage for, 40t
in lower back pain, 510–511
in osteoporosis, 274–275, 275t
Lactulose (Chronulac), 453
Lacunar disease, 524
Lamotrigine
for behavioral disturbances in dementia with manic-like features, 301, 301t
for bipolar depression, 345–349, 348t
for depression, 346t
for epilepsy, 534t
Language
body language, 64
Wong-Baker FACES Pain Rating Scale with Foreign Translations, 129
Lansoprazole, 124
Lantus (insulin glargine), 574
Laryngoscopy, nasopharyngeal, 241
Laser therapy, 205
Last will and testament, 29, 30t
Latanoprost, 210
Laxatives
bulk, 453t
for chronic constipation, 452, 452t
nutrient interactions, 235, 235t
osmotic, 453t
saline, 453t
stimulant, 453t
surfactant, 453t
Leadership, 171, 172–173
Left ventricular ejection fraction, 433
Leg-length discrepancies, 257
Legal issues, 28–36
decisional capacity, 28, 29–32
in home care, 185
informed consent for research, 32
in malnutrition, 238–239
Legionella pneumophila, 542
Legislation, 170–173
Length of stay, 168
Lentigo maligna, 396–397
Lesser metatarsal phalangeal joint dislocation, 515t
Leukemia, 596–597
acute, 589
acute myeloid leukemia, 596–597
chronic lymphocytic leukemia, 597
Leukoaraiosis, 257
Leukoplakia, 403, 403f
Leuprolide acetate, 304
Levalbuterol, 412
Levemir (insulin detemir), 574
Levetiracetam, 534
Levodopa, 235, 235t
Levodopa-carbidopa and delirium, 311t
for Parkinson disease, 520
Levofloxacin, 93, 93t
Leykoaraiosis, 257
Libido, decreased, 488–489, 490t
Lice, 394
Lichen planus, 475
Lichen sclerosis, 474, 475
Lichen simplex chronicus, 388, 475
Lid abnormalities, 205
Lid malposition/exposure, 203–204, 204t
Life-course theory, 10
Life expectancy, 3, 3t
Lifestyle modification
for benign prostatic hyperplasia, 480, 480t
healthy lifestyle counseling, 78t–79t, 82
for hypertension, 442–443
for urinary incontinence, 249
Light therapy, 322–323, 323t
Limb movements
periodic limb movements during sleep, 319–320
restless legs syndrome, 319–320
Linagliptin (Tradjenta), 572t
Linagliptin and metformin (Jentadueto), 573t
Lip cancer, 403
Lipid abnormalities, 570
Lipid-binding resins, 235, 235t
Lipid-lowering therapy, 570
Lipophilic drugs, 88
Liraglutide (Victoza), 573t
Lisinopril, 435t
Literacy, 4, 63
Lithium
for behavioral disturbances in dementia with manic-like features, 301, 301t
for depression, 344
drug interactions, 93, 93t
for personality disorders, 366
to stabilize mood in mania and bipolar depression, 345, 348t
Living arrangements, 4, 4t
Living wills, 31
Long lie, 261
Long-term care. See also Assisted-living facilities; Nursing-home care
fever in frail, older residents, 539–540, 540t
hypertension in, 445
interface with acute care, 169–170
managed long-term care programs (MLTC), 186
minimum criteria for initiation of antibiotic therapy in, 539–540, 541t
requirements for facilities, 172t, 173
urinary incontinence in, 251
Loop diuretics
drug interactions, 93, 93t
for heart failure, 436
and incontinence, 245t
Lorazepam, 312–313, 312t
Lorcet (hydrocodone), 136t
Lortab (hydrocodone), 136t
Index 621
Geriatric Review Syllabus

Low T3 syndrome, 551–552
Louse infestations, 394
Loss of consciousness, sudden, 228
Loss and grief, 22
Losartan, 435

Laboratory tests and imaging, 510–511
history, 509–510
physical examination of, 510, 510

Lower back pain, 507
assessment of, 509–511, 509
CAM for, 100

Lower extremities, 508, 508
physical examination of, 510, 510

Lower urinary tract
age-related changes in, 245
pathophysiology in UI, 245–246, 247

M

Lubiprostone (Amitiza), 453
Lubrication, decreased, 489, 490

Lumbar spine, unstable, 508
Lumbar spinal stenosis, 259, 507–508

Lumpectomy, 594–595
Lung cancer, 594

CAM for, 103
ethnic and racial differences in
cancer, 587
incidence, 587

Lower urinary tract symptoms (LUTS), 244, 479
Lubiprostone (Amitiza), 453
Lubrication, decreased, 489, 490

Lumbar spinal stenosis, 259, 507–508
Lumbar spine, unstable, 508
Lumpectomy, 594–595
Lung cancer, 594

CAM for, 103
ethic and racial differences in
cancer, 587
incidence, 587

Lower respiratory disease, chronic, 4–5, 6

Lower extremities, 508

Lower urinary tract
age-related changes in, 245
pathophysiology in UI, 245–246, 247

Lung cancer, 594

CAM for, 103
ethic and racial differences in
cancer, 587
incidence, 587

Lower urinary tract symptoms (LUTS), 244, 479
Lubiprostone (Amitiza), 453
Lubrication, decreased, 489, 490

Lumbar spinal stenosis, 259, 507–508
Lumbar spine, unstable, 508
Lumpectomy, 594–595
Lung cancer, 594

CAM for, 103
ethic and racial differences in
cancer, 587
incidence, 587

Lymphadenectomy, pelvic, 483
Lymphoma, 596–598
diffuse large B-cell lymphoma, 597
follicular lymphoma, 597
non-Hodgkin lymphoma, 597
Lyrica (pregabalin), 135

M2 inhibitors, 543
MA. See Medicare Advantage
MacArthur Competency Assessment Tool, 30
Macronutrient guidelines, 233
Macronutrient needs, 233
Macular degeneration, age-related, 203,
206–207
Magnesium
drug interactions, 235, 235
RDIs for adults ≥ 71 years old, 234
Magnesium citrate (Citroma), 453
Magnesium-containing antacids, 92, 92
Magnesium hydroxide (Milk of Magnesia), 453
Malignancy
hematologic malignancies, 596–598
humoral hypercalcemia of, 556, 557
Malignant melanoma, 520
Malnutrition, 233–239
Mammography, 77, 78t
Mammography, 77, 78t
Managed care
Medicaid
Medicare
Medicaid
Medicare
Medicaid
Medicare
Medicaid
Medicare

Medicaid Home and Community-Based
Services waiver, 191
Medical decisions, 29, 30t

Medical directors
requirements for long-term care
facilities, 172, 173
residential-care benefits, 7

Medical ethics, 28–29
Medical homes, 37, 190–191
Medical interpreters, 63–64
Medical-legal interface, 108
Medical savings accounts (MSAs), 41
Medicare, 3, 37, 40t, 42
advantages and disadvantages of, 44,
44t

Marital status of community-dwelling older
Americans, 4, 4t
Masked facies, 528
Massage, 97–98
for musculoskeletal pain, 499
MAST (Michigan Alcoholism Screening
Test)—Geriatric Version, 372
McGill Pain Questionnaire, 129, 337
MDRD (Modified Diet in Renal Disease)
formula, 89, 111–113, 460
MDS. See Minimum Data Set;
Myelodysplastic syndromes
Meals-on-Wheels, 294
“Meaningful Use” standard, 49
Mechanical loading, 330–331
Mechanical ventilation, 149
Meclizine, 124
Mediators, 23–24
Medicaid, 3, 37, 40t, 42
advantages and disadvantages of, 44,
44t
assisted-living benefits, 187
continuing-care retirement
community benefits, 188
day care benefits, 185
dual eligibles, 42–43, 47
future directions, 49–50
glaucoma-related payments, 209
hearing aid benefits, 219
hospice benefits, 120
requirements for long-term care
facilities, 172, 173
residential-care benefits, 7

Medical ethics, 28–29
Medical homes, 37, 190–191
Medical interpreters, 63–64
Medical-legal interface, 108
Medical savings accounts (MSAs), 41
Medicare, 3, 37–43
assisted-living benefits, 187
billing codes and reimbursement for
home visits, 184, 184t
care venues, 179
cochlear implant coverage, 220
continuing-care retirement
community benefits, 188
day hospital benefits, 185
dual eligibles, 42–43, 47
fee-for-service (FFS), 37, 38–39, 40t, 44, 44t
functional limitations of enrollees, 4, 6f
future directions, 49–50
“Geographical Practices Cost Indices,” 182
glaucoma-related payments, 209
guidelines for erythropoietin therapy, 209
hospice benefits, 33–34, 120
home-care benefits, 184
home-care benefits, 184
home-health benefits, 154
hospice benefits, 33–34, 120
house-call benefits, 184
mobility-related device benefits, 164
nursing-home care benefits, 168, 175
out-of-pocket expenses, 39
Part A, 37–39, 40
Part B, 37–39, 40
Part C, 37
Part D, 37, 40, 41, 43, 49, 86
postacute care benefits, 154
preventive health benefits, 84, 86
private contracts, 39
prospective payment system (PPS), 46, 168, 182
prospective reimbursement, 154, 154t
rehabilitation benefits, 152–153, 153t, 154
requirements for long-term care facilities, 172, 173
requirements for rehabilitation sites, 153t
skilled-nursing-facility benefits, 168
transitions in care, 177
“Welcome to Medicare” preventive visits, 44, 86
Medicare Administrative Contractors, 38
Medicare Advantage (MA), 37, 39–41, 40t
advantages and disadvantages of, 44, 44t
fee-for-service, 45, 45t
healthcare provider payments, 45, 45t
types of plans, 39–41
Medicare Health Maintenance Organizations (HMOs), 39–40
Medicare Health Outcomes Survey, 49
Medicare Personal Plan Finder, 43, 49
Medicare Prescription Drug Improvement and Modernization Act, 49
Medicare Prescription Drug Plan Finder (CMS), 41
Medicated urethral system for erection (MUSE), 493, 494
Medication-induced parkinsonism, 530, 530t
Medication Regimen Complexity Index, 60
Medication review
annual drug regimen review, 95
brown-bag evaluation, 94, 309
for demented patients, 294
discharge medication regimen, 179
at hospital admission, 143, 143t, 147
for preventing falls, 268t
requirements for long-term care facilities, 172t, 173
screening tool of older persons’ potentially inappropriate prescriptions (STOPP), 146–147
Medication trays, 95
Medications. See Drugs; Pharmacotherapy; specific medications
Medigap, 37, 40, 42
advantages and disadvantages of, 44, 44t
Megestrol, 238
Meglitinides, 572t
Melanoma, 396–397, 397t
acral lentiginous, 397, 397t
malignant, 520
superficial spreading, 397, 397t
Melatonin, 321, 326, 564
Melatonin receptor agonists, 324, 325t
Memantine, 293
Membranoproliferative glomerulonephritis, 464
Membranous nephropathy, 464
Memorial Delirium Assessment Scale, 306
Memory problems. See also Cognitive impairment; Dementia
three-item recall test for, 83
Memory retraining, 289
Men
alcohol use among, 371
cardiovascular disease in, 415, 415t
erectile dysfunction in, 490–494
functional limitations of Medicare enrollees, 4, 6f
gallstones in, 451
hormonal influences in, 273–274
indications for osteoporosis screening, 276, 276t
leading causes of death for, 4–5, 6t
life expectancy of, 3, 3t
marital status and living arrangements of, 4, 4t
osteoporosis in, 275
prostate disease, 479–487
RDIs for micronutrients, 233–234, 234t
recommended requirements of vitamin D, 278
sexual problems, 82
stroke in, 523
testosterone supplementation for, 561–562, 562t
urinary tract infections in, 543, 544
Mendelson syndrome, 241
Meniere disease, 218, 221
Meningitis, bacterial, 547
Meningococcal vaccination, 539, 540t
Mениscus, 503, 503t
Menopausal symptoms
CAM for, 102
treatment of, 473
Menopause, 473
Mental health
acute mental status change, 306, 307t
health insurance coverage for outpatient care, 40t
rehabilitation and, 156–157
requirements for long-term care facilities, 172t, 173
self-efficacy beliefs and, 24, 24t
social networks and, 25–26, 26t
Mental health problems, 372
diagnosis and treatment of, 381–382
mental retardation with, 379, 380–382
requirements for long-term care facilities, 172t, 173
Mental retardation, 378–384
definition of, 378
with developmental disabilities, 382–384, 383t
developmental disabilities and comorbidity, 382–384
diagnostic issues, 379–380
medical disorders with, 382
mental disorders with, 379, 380–382
prevalence of, 378–379
requirements for long-term care facilities, 172t, 173
social conditions with, 382
treatment issues, 379–380
Meperidine, 138, 311t
Mesangial glomerulonephritis, 464
Metabolic disease, 246t
Metabolic disorders, 550–565
Metabolic encephalopathy, 305
Metabolism
  age-associated changes in, 88
  of drugs, 88
  preoperative assessment and
  management of, 111–113
METAGLIP (glipizide and metformin), 573t
Metamucil (psyllium), 453t
Metatarsal phalangeal joint dislocation, 515
Metastatic breast cancer, 596
Metamucil (psyllium), 453
_METAGLIP (glipizide and metformin),
  573t
Metformin (Glucophage, Riomet, Glumetza)
  for diabetes mellitus, 571, 572t
  glipizide and metformin
  (METAGLIP), 573t
  glyburide and metformin
  (Glucovance), 573t
  linagliptin and metformin
  (Jentadueto), 573t
  nutrient interactions, 235, 235t
  repaglinide and metformin
  (PrandiMet), 573t
  rosiglitazone and metformin
  (Avandamet), 573t
  saxagliptin and metformin
  (Kombiglyze XR), 573t
  sitagliptin and metformin (Janumet),
  573t
Methadone, 374–376, 375t
Methicillin-resistant _Staphylococcus aureus_
  (MRSA), 542–543
Methylcellulose (Citrucel), 453
Methylmalonic acid, 583
Methylprednisolone
  for CPPD, 503–504
  for dermatomyositis, 506
  for giant cell arteritis, 504
  for gout, 502
  for polymyositis, 506
Metoclopramide
  adverse drug events, 92, 92t
  for nausea, 124t
Metolazone, 436
Metoprolol, 435t
Metronidazole
  for _C difficile_ colitis, 457
  for diverticulitis, 455
Mexican Curanderos, 98
Mexiletine (Mexitil), 135t
MGUS (monoclonal gammopathy of
  uncertain significance), 597–598
Michigan Alcoholism Screening Test
  (MAST)—Geriatric Version, 372
Micrographia, 528
Micronase (glyburide), 572t
Micronutrient requirements
  age-related changes in, 233–234
  recommended dietary intakes, 233–
  234, 235t
Micronutrient supplements, 237–238
Microvascular complications of diabetes
  mellitus, 570
Midodrine, 268t
Miglustat (Zavesca), 453
Miglitol (Glyset), 572t
Midodrine, 268
Midodrine, 268
Mild cognitive impairment
diagnostic features and treatment of,
  288t
  differential diagnosis of, 287
Milk of Magnesia (magnesium hydroxide),
  453t
Milnacipran (Savella), 135t
Migraine headache, 527
Mitral stenosis, 423, 424
Mitral regurgitation, 423, 424t
Mitral stenosis, 423, 424t
Mixed dementia, 284
Mixed hearing loss, 213t
Mixed UI, 244, 246
MLTC (managed long-term care programs), 186
MMSE (Mini–Mental State Examination),
  29–30, 55, 83, 145, 286, 287t
Mnemonic for reversible causes of
delirium, 308t
Mobility, 331
Mobility aids, 162–163, 163–164, 163t
for gait disorders, 259–260
Mobility assessment
  activities of daily living (ADLs), 53,
  54t
  Performance-Oriented Mobility
  Assessment (POMA), 54, 258,
  265
  rapid screening followed by
  assessment and management of,
  52, 53t
Mobility training, 269t
MoaCA (Montreal Cognitive Assessment),
  55, 286, 287t
Modafinil, 346t
Moderators, 25–27
Modified Diet in Renal Disease (MDRD)
  formula, 89, 111–113, 460
Mono-Gesic (salsalate), 136t
Mirtazapine
  for depression, 344, 346t
  for depressive features of behavioral
disturbances in dementia, 299–
  300, 300t
  for insomnia, 294, 324, 325t
for sleep disturbances in dementia,
  303
for undernutrition, 238
Mistreatment, 104–108
definition of, 104
  financial, 106
  incidence of, 104
  institutional, 107
  interventions for, 107–108
  medical-legal interface, 108
  physical, 105
  prevalence of, 104
  prevention of, 104
  psychological abuse, 105–106
  questions to guide intervention for,
  107
  risk factors for, 104, 105t
  screening for, 84, 105, 106t
  signs of abuse, 105, 106t
Mistreatment history, 105
Mitochondrial DNA (mtDNA) theory of
  aging, 10, 11t
Mitral regurgitation, 423, 424t
Mitral stenosis, 423, 424t
Mixed dementia, 284
Mixed hearing loss, 213t
Mixed UI, 244, 246
MLTC (managed long-term care programs), 186
MMSE (Mini–Mental State Examination),
  29–30, 55, 83, 145, 286, 287t
Mnemonic for reversible causes of
delirium, 308t
Mobility, 331
Mobility aids, 162–163, 163–164, 163t
for gait disorders, 259–260
Mobility assessment
  activities of daily living (ADLs), 53,
  54t
  Performance-Oriented Mobility
  Assessment (POMA), 54, 258,
  265
  rapid screening followed by
  assessment and management of,
  52, 53t
Mobility training, 269t
MoaCA (Montreal Cognitive Assessment),
  55, 286, 287t
Modafinil, 346t
Moderators, 25–27
Modified Diet in Renal Disease (MDRD)
  formula, 89, 111–113, 460
Mono-Gesic (salsalate), 136t
Negative-pressure wound therapy, 336
Neglect. See also Mistreatment
risk factors for inadequate caregiving, 104, 105t
self-neglect, 107, 354
signs of, 105, 106t
Neoptasia
adrenal, 559–560
skin, 519–520
vulvar, 475
Nephritis
acute interstitial, 466
deaths due to, 4–5, 6t
Nephropathy, membranous, 464
Nephrosis, 4–5, 6t
Nephrotic syndrome, 463–464
deaths due to, 4–5, 6t
Nervous system
age-related changes, 13, 14t
age-related pathologies, 18t
Neuraminidase inhibitors, 543
Neuregulins, 238
Neurodermatitis, 388, 475
Neurologic diseases and disorders, 523–537
CAM for, 101–102
and incontinence, 246t
Neurologic testing, 231
quality indicators for dementia, 294
Neuroma, 518
Neuromuscular electrical stimulation, 499
Neurontin (gabapentin), 135t
Neuropathic pain, 129, 130, 131t
Neurontin (gabapentin), 135t
Neurology, 238
Nociceptive pain, 129, 131t
Nociceptors, 130t
Nocturia, 246, 246t
Nocturnal polyuria, 247t
Nodular basal cell carcinoma, 396
Nodular melanoma, 397
Nodular thyroid disease, 553–554
Non-Hodgkin lymphoma, 597
Nonadherence to medication regimens, 95
Nonconvulsive status epilepticus, 533
Nonsteroidal anti-inflammatory drugs (NSAIDs)
adverse drug events, 92, 92t, 235
drug interactions, 93, 93t
gastric complications, 450
and incontinence, 245t, 250
for musculoskeletal pain, 500
for persistent pain, 133, 135t–136t
for polymyalgia rheumatica, 504
Nonthyroidal illness syndromes, 551
Nonverbal communication, respectful, 64
Norco (hydrocodone), 136t
Normative ethics, 28
Norpramin (desipramine), 135t
Norton Scale, 329
Nortriptyline (Aventyl, Pamelor)
for depression, 344, 346t
for depressive features of behavioral disturbances in dementia, 299–300, 300t
for persistent pain management, 135t
Novolin (insulin), 574t
Novolin 70/30 (isophane insulin + regular insulin), 574t
NovoLog (insulin aspart), 574t
NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart), 574t
Noxious stimulus, 130t
NPH insulin (Humulin, Novolin), 574t
NPI (Neuropsychiatric Inventory), 297
NPUAP (National Pressure Ulcer Advisory Panel), 332, 334t
NSAIDs, See Nonsteroidal anti-inflammatory drugs
Nucynta (tapentadol), 137t
Nucynta ER (tapentadol extended release), 137t
Numeric Rating Scale, 129
Nurse practitioners, 40t
in nursing home, 174–175
rehabilitation team role, 155, 156t
Nurses Improving Care of Health System Elders (NICHE), 150
Nursing, 155, 156t
Nursing facilities, 7
medical directors of, 171t, 172–173
staffing patterns, 168–169
Nursing-home care, 166–176
availability of, 167–168
clinical practice guidelines for, 175
demographic characteristics of older adults in, 166–167, 167t
falls risk in, 263t
fee-for-service, 47
fever in, 539–540
financing, 47, 168
functional characteristics of older adults in, 166–167, 167t
health insurance coverage for, 40t, 48t
legislation influencing, 170–173
length of stay in, 168
managed care, 47
medical care issues, 173–174
occupancy rates, 167
physician practice in, 174–175
physician responsibilities in, 173t, 174
treatment factors, 169
population, 166–167, 167t
postacute care, 167–168
quality issues, 170–173
quality measures for, 170–171, 170t
sleep in, 321–322
staffing patterns, 168–169
standards of care, 239
unacceptable weight loss, 239–239
urinary incontinence in, 245, 251–252
Nursing-home–acquired pneumonia, 542–543
Nutrition
for chronic kidney disease, 469
drug-nutrient interactions, 235, 235t
for hospitalized patients, 143t, 147–148
intake, 234–235
interventions, 143t, 237–238
malnutrition, 233–239
oral, 237–238
for prevention of pressure ulcers, 330
to reduce risk of osteoporosis, 274, 274t
risk factors for poor status, 236, 236t
standards of care for, 239
syndromes, 236–237
undernutrition, 236
Nutrition assessment, 54, 234–236
multi-item tools for, 236
rapid screening followed by
assessments, 52, 53t
screening evaluations, 84
threshold to trigger, 239
Nutrition Screening Initiative, 236
Nutritional supplements, 237–238
for pressure ulcers, 333
safety issues, 98, 99t
O
OASIS (Outcome and Assessment
Information Set), 154, 182
Obesity, 236–237
cardiovascular risk, 418
prevalence of, 236–237
recommendations for, 84
OBRA (Omnibus Budget Reconciliation
Act), 107, 166, 170–171, 172, 238–239
Obstructive pulmonary disease, chronic,
410–411
anxiety and, 355
Obstructive sleep apnea, 246t, 318–319,
321, 412–413
Occupational therapy (OT), 40t
for dementia, 294
for pain, 500
rehabilitation team role, 155, 156t
Ocd, 125t
Odd or eccentric behaviors, 362, 363t
Office-based house-call programs, 183–
184
Office visits, 52, 291
25(OH)D levels, 278, 554
Olanzapine
for agitated delirium, 312–313, 312t
for depression, 344–345
dosing and adverse events of, 358,
359t
for psychosis in dementia, 301–302,
302t
to stabilize mood in mania and
bipolar depression, 348t
Olanzapine/fluoxetine, 348t
Older Americans Act, 188, 237, 294
Olfactory dysfunction
medications that cause, 405, 406t
nonpharmacologic causes of, 405,
406t
Olivopontocerebellar atrophy, 530
Olmesartan, 435t
Omega-3 fatty acids, 98, 99t
Omeprazole, 124
Ondansetron, 124
Oncology, 587–598.
Cancer
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
Oncology, 587–598.
See also
Oncology.
medications, 40t
mental health care, 40t
patient selection for interventions, 192
rehabilitation services, 153t, 155
systems of care, 189–193
Outpatient consultation, 189–190
Ovarian cancer, 80
Overprescribing, 90–91, 90t, 91t, 94
Overweight, 421
94
Overweight, 421
Overprescribing, 90–91, 90

8th Edition
Geriatric Review Syllabus

in cognitively impaired adults, 130–

chronic, 128, 382–384, 383

central, 130
back pain, 507–511
acute, 128
Pain
Paget disease of bone, 557–558
Padua Prediction Score, 148
PAD.
Peripheral arterial disease
See indications for, 428–429, 429
Pacemakers, 232
PACE (Program of All-inclusive Care of
the Elderly), 47, 186
Pacemakers, 232
indications for, 428–429, 429t
PAD. See Peripheral arterial disease
Padua Prediction Score, 148
Paget disease of bone, 557–558
Pain
acute, 128
back pain, 507–511
central, 130t
chronic, 128, 382–384, 383t
in cognitively impaired adults, 130–
131, 132t
definition of, 128
diffuse, 498–499
evaluation of, 497–499
heel pain, 518
mixed or unspecified, 130, 131t
myofascial, 129
neck pain, 511–512
neuropathic, 129, 130, 131t
nociceptive, 129, 131t
persistent, 128–139
phantom limb pain, 162
somatic, 129, 131t
terms used in care of patients in, 130t

types of, 129, 131t
visceral, 129, 131t
wind-up, 130t
Pain Disability Scale, 129
Pain disorder, 366
Pain intensity scales, 129
Pain management, 131–138
in cognitively impaired, 145–146
nonpharmacologic therapy, 131–132, 499
pharmacologic therapy, 132–138, 500
postoperative, 117
in vertebral compression fractures, 282–283
Paliperidone
dosing and adverse events of, 358, 359t
for psychosis in dementia, 301–302, 302t
Palliative care, 119–127
cultural aspects of, 119–120
depth of palliation, 450
ethnographic data, 119–120
for frailty, 201
hospice, 120
overall care near death, 119
quality indicators for, 121
for terminally ill, 122–126
Palsy, progressive supranuclear, 530
Parkinson disease, 527–530
Parkinsonian syndromes, 530–531, 530t
Parkinsonism
medication-induced, 530, 530t, 532
vascular, 530, 530t
Paroxysms, 320
Paroxetimne
for depression, 299, 346t
for depressive features of behavioral
disturbances in dementia, 300t
drug interactions, 93, 93t
Passive-aggressive personality disorder
features of, 362, 363t
therapeutic strategies for, 365, 365t
Past medical history, 143, 143t
PATH (problem adaptation therapy), 349t,
350
Patient-centered medical home (PCMH), 190
Patient Centered Medical Homes, 37
Patient education
about diabetes, 574–575
guidelines for prevention of falls, 267
medications for, 171t, 172–173
Patient Health Questionnaire (PHQ), 55
indications to start antidepressant
treatment based on, 341–342, 342t
response guidelines based on, 342,
342t
screening questions and complete
assessment, 341–342, 341t
Patient preferences, 58–59
Patient safety, See Safety
Patient Self-Determination Act (PSDA), 48
Pay for performance, 49
PCI. See Percutaneous coronary
intervention
PCMH (patient-centered medical home), 190
PDGF (platelet-derived growth factor),
334–335
PE. See Pulmonary embolism
Peak expiratory flow meters and inhalers, 411
Pediculosis capitis, 394
Pediculosis corporis, 394
Pediculosis pubis, 394
Pegaptanib sodium, 207
Pelvic examination, 472–473
Pelvic floor support disorders, 475–477
Pelvic lymphadenectomy, 483
Pelvic muscle exercises, 249
Pelvic organ prolapse, 475–476, 476t

P
PACE (Program of All-inclusive Care of
the Elderly), 47, 186
Pacemakers, 232
indications for, 428–429, 429t
PAD. See Peripheral arterial disease
Padua Prediction Score, 148
Paget disease of bone, 557–558
Pain
acute, 128
back pain, 507–511
central, 130t
chronic, 128, 382–384, 383t
in cognitively impaired adults, 130–
131, 132t
definition of, 128
diffuse, 498–499
evaluation of, 497–499
heel pain, 518
mixed or unspecified, 130, 131t
myofascial, 129
neck pain, 511–512
neuropathic, 129, 130, 131t
nociceptive, 129, 131t
persistent, 128–139
phantom limb pain, 162
somatic, 129, 131t
terms used in care of patients in, 130t

628 Geriatric Review Syllabus, 8th Edition
Pelvic Organ Prolapse Quantification, 475
Penile prosthesis, 493t, 494
Peptic ulcer disease, 451
Percocet (oxycodeone, immediate release), 136t
Percodan (oxycodeone, immediate release), 136t
Percutaneous coronary intervention (PCI) for acute coronary syndrome, 420
for chronic CAD, 422
Percutaneous endoscopic gastrostomy or jejunostomy, 242
Performance-Oriented Mobility Assessment (POMA), 54, 258, 265
Pharmacotherapy, 87–96
age-associated changes in, 89–90
chemotherapy issues, 591, 592t
Pharmacokinetics
age-associated changes in, 87–89
chemotherapy issues, 591, 592t
Pharmacotheapy, 87–96
adverse drug events, 91t, 92, 92t
for agitated delirium, 312–313, 312t
anticonvulsant therapy, 534
for anxiety disorders, 355–356
for benign prostatic hyperplasia, 480, 480t
brown-bag evaluation of, 94
for dementia, 292–294
for depression, 344–345
for diastolic HF, 437
for frailty, 200
for hypertension, 442–444
inappropriate prescribing, 90–91, 90t, 91t
investigational agents for osteoporosis, 282
for mania, 345, 348t
non-insulin agents for diabetes mellitus, 571–574, 572t–573t
nonadherence to regimens, 95
optimizing, 60, 90–91
for osteoporosis, 278–282, 279t
for pain, 132–138, 500
for persistent pain, 132–133, 135t–137t
polypharmacy, 60
prescribing cascade, 92
principles of prescribing, 94, 94t
to reduce or eliminate in management of delirium, 310, 311t
for sarcopenia, 238, 238t
for schizophrenia and schizoaffective-like syndromes, 358–359
screening tool of older persons’ potentially inappropriate prescriptions (STOPP), 146–147
for sleep problems, 323–324, 325t
suboptimal, 143t, 146
for substance abuse, 374–376
that may relieve constipation, 452, 453t
for undernutrition syndromes, 238
Pharyngeal dysphagia, 240–241
Phenobarbital, 311t, 534t
Phentolamine, 493–494, 493t
Phenytoin
adverse drug events, 235
and delirium, 311t
drug interactions, 93, 93t
for epilepsy, 534t
nutrient interactions, 235, 235t
Phlebotomy, 585
Phobia
social, 353, 355, 355t
specific, 353, 355, 355t
treatment strategies for, 355, 355t
Phosphodiesterase type 5 inhibitors, 92, 92t
Phosphorus, 468–469
Phototherapy, 336
Photoaging, 386
Physical activity, 69–75. See also Exercise assessing, 73
baseline activity, 69
benefits of, 69–70
for chronic constipation, 452, 452t
counseling for, 73, 79t, 82
criteria that define frailty, 198t
dementia, 291
economic benefits of, 70
guidelines for plans, 73
for pain, 132
prescription for, 73
preventive health benefits of, 69–70
promoting, 72–74
providing assistance in increasing, 73–74
Rapid Assessment of Physical Activity, 73
recommendations for, 70–72, 71t
relative exercise intensity, 69
risks of, 74
screening for, 72
therapeutic benefits of, 70
Physical Activity Guidelines Advisory Committee, 72
2008 Physical Activity Guidelines for Americans (HHS), 71, 72
Physical assessment, 52–55
Physical dependence, 134
Physical disability
excess, 371–372
Personhood, 35–36
Pes cavus, 515t
Pes planus, 514–516, 515t
Pes valgo planus, 515t
Pessaries, 251, 476
Phantom limb pain, 162
Periostitis, 515
Periodontium, 400–401
Periodontitis, 400
Periodontal anatomy, 399, 399t
Periodontal ligament, 400
Peripheral arterial disease, 429–430
diagnosis of, 429–430
and foot, 522
treatment of, 430
Peripheral neuropathy, 535–536
Peripheral vascular disease, 157
Peripheral venous insufficiency, 246t
Peroxisome proliferator-activated receptor-delta, 238t
Peroxisome proliferator-activated receptor-gamma coactivator 1-α, 238t
Perphenazine
dosing and adverse events of, 358, 359t
for nausea, 124t
for psychosis in dementia, 302t
Persistent pain, 128–139
assessment of, 128–130
nonopioid adjuvant medications for, 137–138
pharmacotherapy for, 132–133, 135t–137t
treatment of, 131–138
Personality disorders, 362–366
diagnostic challenges, 363–364
differential diagnosis of, 364
epidemiology of, 362–363
features of, 362, 363t
long-term course, 364–365
not otherwise specified, 362
provisional, 362, 363t
therapeutic strategies for, 365–366, 365t
Perindopril, 435
Performance-based functional assessment, 257–258
Performance-Oriented Mobility Assessment (POMA), 54, 258, 265
Percutaneous endoscopic gastrostomy or jejunostomy, 242
for acute coronary syndrome, 420
for chronic CAD, 422
Percutaneous endoscopic gastrostomy or jejunostomy, 242
for acute coronary syndrome, 420
for chronic CAD, 422
Performance-Oriented Mobility Assessment (POMA), 54, 258, 265
Performance-based functional assessment, 257–258
Performance-Oriented Mobility Assessment (POMA), 54, 258, 265
Percutaneous endoscopic gastrostomy or jejunostomy, 242
for acute coronary syndrome, 420
for chronic CAD, 422
Percutaneous endoscopic gastrostomy or jejunostomy, 242
for acute coronary syndrome, 420
for chronic CAD, 422

Plantar verruca, 519–520
Plate, 400
Platelet-derived growth factor (PDGF), 334–335
Platelet function disorders, 584
Platelets, 584–585
PLMS (periodic limb movements during sleep), 319–320
PMR (polymyalgia rheumatica), 504
Pneumococcal pneumonia, 241
Pneumococcal vaccination
  - in hospitalized patients, 143t, 148
  - immunization schedule for adults ≥65 years old, 539, 540t
  - recommendations for, 78t, 85, 543
Pneumonia, 542–543
  - aspiration, 241
  - community-acquired, 542
  - deaths due to, 4–5, 6t
  - guidelines for therapy, 542
  - hospital-acquired, 542–543
  - nursing-home–acquired, 542–543
  - pneumococcal, 241
  - and rehabilitation, 156
POCD (postoperative cognitive dysfunction), 309
Political correctness, 62
Polycarbophil (FiberCon, others), 453t
Polycythemia vera, 585–586
Polyethylene glycol (Miralax), 453
Polymyalgia rheumatica, 504
Polymyalgia, 505–506
Polypharmacy, 60
Polyps, colonic, 458, 458t
Postherpetic neuralgia, 205, 392–393
Posture, 231
Postural abnormalities, 528
Postural hypotension, 231
  - guidelines for prevention of falls, 267
  - interventions for preventing falls, 268t
Postural stability tests, 265
Postvoid residual (PVR)
  - increased, 244, 245, 248
  - testing, 245–249
Potassium, 234t
Potassium balance disorders, 463
Potassium-sparing diuretics
  - adverse drug events, 92, 92t
  - drug interactions, 93, 93t
Potassium supplements
  - adverse drug events, 92, 92t, 235
  - drug interactions, 235, 235t
Poverty, 359
Poverty rates, 3
Power mobility devices, 164
PPD (purified-protein derivative) skin tests, 545
PPOs (preferred provider organizations), 40
PPS (prospective payment system), 168, 182
Pra (Probability of Repeated Admission) Questionnaire, 192
Pramipexole
  - for Parkinson disease, 529t
  - for periodic limb movement disorder, 320
  - for restless legs syndrome, 320
Pramlintide (Symlin), 573t
PrandiMet (repaglinide and metformin), 573t
Prednisone
  - for dermatomyositis, 506
  - for giant cell arteritis, 504
  - for giant cell arteritis, 504t
  - for gout, 502
  - for musculoskeletal pain, 500
  - for polymyalgia rheumatica, 504t
  - for polymyalgia, 506
  - for rheumatoid arthritis, 502t
Preferred provider organizations (PPOs), 40
Pregabalin (Lyrica)
for epilepsy, 534t
and incontinence, 245t
for persistent pain, 135t, 138
Prehabilitative approach, 150
Prehypertension, 440, 440t
Preoperative assessment and management, 109–113
Presbycusis, 214–215
screening tool of older persons’
principles of, 94, 94
optimizing, 60, 90–91
of frailty, 200
health insurance coverage for
services, 40t
of hip fracture recurrence, 160
HIV, 547
of infections, 541
of microvascular complications of
diabetes mellitus, 570
of mistreatment, 104
of osteoporosis, 277–282
physical activity benefits for, 69–70
of pressure ulcers, 143t, 147, 329–331, 331t
recommended measures for, 76,
78r–79r
of stroke, 524–525
of venous thromboembolism, 143t, 148
“Welcome to Medicare” preventive visits, 44
Primary care
comprehensive geriatric assessment
(CGA) in, 189–190
enhanced, 190–191
geriatrics in, 189–192
GRACE model of, 190–191
Primary providers, 182–183
PRIME-MD, 341
Primidone, 311t
Private contracts, 39
Private FFS plans, 40
Probability of Repeated Admission
Questionnaire (Pra), 192
Probemecid, 503
Problem adaptation therapy (PATH), 349t, 350
Problem drinking, 374–376, 375t
Problem-solving therapy, 349t, 350
Problem substance use, 369
Prochlorperazine, 124t
Productivity, 25
Progesterone, 303–304
Progestins, 473
Prognosis, 59
Program of All-inclusive Care of the Elderly (PACE), 47, 186
Progressive supranuclear palsy, 530t, 531
Prokinetic agents, 124t
of atherosclerotic complications of
diabetes mellitus, 569–570
available health measures for, 76,
78r–79r
counseling on, 85–86
of falls, 264f, 265, 266–269, 268t
of frailty, 200
health insurance coverage for
services, 40t
of hip fracture recurrence, 160
HIV, 547
of infections, 541
of microvascular complications of
diabetes mellitus, 570
of mistreatment, 104
of osteoporosis, 277–282
physical activity benefits for, 69–70
of pressure ulcers, 143t, 147, 329–331, 331t
recommended measures for, 76,
78r–79r
of stroke, 524–525
of venous thromboembolism, 143t, 148
“Welcome to Medicare” preventive visits, 44
Primary care
comprehensive geriatric assessment
(CGA) in, 189–190
enhanced, 190–191
geriatrics in, 189–192
GRACE model of, 190–191
Primary providers, 182–183
PRIME-MD, 341
Primidone, 311t
Private contracts, 39
Private FFS plans, 40
Probability of Repeated Admission
Questionnaire (Pra), 192
Probemecid, 503
Problem adaptation therapy (PATH), 349t, 350
Problem drinking, 374–376, 375t
Problem-solving therapy, 349t, 350
Problem substance use, 369
Prochlorperazine, 124t
Productivity, 25
Progesterone, 303–304
Progestins, 473
Prognosis, 59
Program of All-inclusive Care of the Elderly (PACE), 47, 186
Progressive supranuclear palsy, 530t, 531
Prokinetic agents, 124t
Prolapse
pelvic organ, 475–476, 475t
surgery for, 476–477
Promethazine, 124t
Prompted voiding, 249, 250, 251
Propantheline, 250
Propulsion, 255t
Prospective payment system (PPS), 46, 168, 182
Prostaglandins, 209, 210t
Prostate cancer, 481–486, 596
advanced, 484t, 486
CAM for, 103
castrate-resistant, 596
diagnostic tests, 482–483
ethnic and racial differences in
incidence, 507
expectant or conservative
management of, 485
grading, 483
hormonal therapy for, 591
incidence and epidemiology of, 481
locally advanced, 484t, 486
management approaches for, 484t, 485–486
staging, 483, 483t
surveillance, 485
symptoms of, 481
Prostate cancer screening, 482–483
tamponade, 482–483
tamponade, 482–483
tamponade, 482–483
tamponade, 482–483
tamponade, 482–483
tamponade, 482–483
tamponade, 482–483
tamponade, 482–483
tamponade, 482–483
tamponade, 482–483
tamponade, 482–483
Prostatectomy, radical, 484
Prostatectomy, radical, 484
Prostatectomy, radical, 484
Prostatitis, 486–487
Prostatic hyperplasia, benign, 479–481
CAM for, 102
Prostatism, 479
Prostatitis, 486–487
Prostheses, penile, 493t, 494
Prosthetic device infections, 546
Prosthetic rehabilitation, 162
Prosthetists, 155, 156
Prostaglandins, 209, 210t
Pruritus, 390
Proxy, 30
Puritus, 390
Pseudo-obstruction, acute colonic, 457
Pseudoaddiction, 130t, 134
Pseudoclaudication, 506
Pseudodisease, 77
Pseudogout, 503
Psudodemembranous colitis, 457
Psoriasis, 390–391, 390t
PSOs (provider-sponsored organizations), 40
PSF (progressive supranuclear palsy), 530t, 531
Psychiatric disorders
in aging adults with mental retardation, 380–382
CAM for, 101
diagnosis and treatment of, 381–382
and incontinence, 246t
Psychiatry, 339–384
Psychoactive medications, 293–294
Psychodynamic therapy, 349t, 350
Psychologic assessment, 55
Psychologic interventions, 132
Psychological abuse, 105–106
Psychologic assessment, 55
Psychodynamic therapy, 349–350
Psychoactive medications, 293–294
Psychiatry, 339–384
Psychotherapy
for alcohol dependence, 374–376, 375t
for anxiety disorders, 356
for depression, 349, 350–351
emotion-oriented, 289
Psychosocial functioning, 172, 173
Psychosocial interventions
for dementia, 289
for depression, 350–351
Psychosocial issues, 20–27
Psychosocial theories of aging, 10
Psychotherapy
for alcohol dependence, 374–376, 375t
for anxiety disorders, 356
for depression, 349, 350–351
emotion-oriented, 289
Psychotic depression, 343
Psychotic disorders, 357–361
Psychotic symptoms
definition of, 357
in delirium and delusional disorder, 359
in dementia, 359–360
in mood disorders, 359
Psychotropic medications, 366
Psyllium (Metamucil), 453t
PT (physical therapy), 40t
for dementia, 294
for gait disorders, 258
for pain, 132, 499
for Parkinson disease, 101
for preventing falls, 268t
rehabilitation team role, 155, 156t
PTHrp (parathyroid hormone-related peptide), 556–557
Pulmonary disease, 409–414
chronic obstructive pulmonary disease, 355, 410–411
with developmental disabilities, 382–384, 383t
guidelines for risk assessment and perioperative management of, 111
and incontinence, 246t
Pulmonary embolism
differential diagnosis of, 431
guidelines for prophylaxis, 115, 116t
Pulmonary fibrosis, idiopathic, 413
Pulmonary system
age-related changes, 14t, 15–16, 408
age-related pathologies, 18t
Pulmonary thromboembolism, 413–414
Pure red cell aplasia, 580
Purified-protein derivative (PPD) skin tests, 545
PV (polycythemia vera), 585–586
PVD (peripheral vascular disease), 157
PVR. See Postvoid residual
Pyelonephritis, 544
Pyrazinamide, 545
Pyridoxine, 582
Pyridoxine, 582
Quetiapine
for agitated delirium, 312–313, 312t
dosing and adverse events of, 358, 359t
for Parkinson disease and hallucinations, 360
for psychosis in dementia, 301–302, 302t
to stabilize mood in mania and bipolar depression, 340t
Quinapril, 435t
R
Racial differences
in cancer diagnosis and survival, 587
in cancer incidence, 587
Radiation therapy
for cancer, 593
external beam, 484t, 485–486
postoperative, after lumpectomy, 594–595
for prostate cancer, 484t, 485–486
Radical prostatectomy, 484t, 485
Radiculopathy, 535
Radiographs, 496–497
Raloxifene, 279t, 280
Ramelteon, 324, 325t
Ranipril, 435t
Ramping technique, 413
Ranibizumab, 207
Ranitidine, 124
RANK ligand inhibitor (denosumab), 279t, 281–282
Ranolazine, 422
Rapid Assessment of Physical Activity, 73
Rapid screening, 52, 53t
Rasagiline, 529
Rate of living theory of aging, 11t, 12
Rational Recovery, 373
Raynaud phenomenon, 505
RDAs (recommended dietary allowances), 233–234
Reality orientation, 289
Recall test, three-item, 83
Recombinant tissue-plasminogen activator (alteplase), 525–526
Recommendation for prophylaxis, 111, 116t
Recommended dietary allowances (RDAs), 233–234
Reflex syncope, 231
Reflux, gastroesophageal, 448–449
Refractive error, 205–206
Refusal of treatment, 28
forgoing and discontinuing interventions, 32–33
right to, 32–33
Rehabilitation, 152–165
adaptive methods for, 164–165
for amputation, 162
approaches and interventions, 157 cardiac, 420, 423
cognitive, 289
comorbid conditions and, 155–157

Q
Quality Improvement System for Managed Care (QISMC), 48
Quality Indicator Survey (QIS), 171
Quality of care
medical director responsibilities for, 171t, 172–173
nursing-home care, 170–173
requirements for long-term care facilities, 172t, 173
Quality of life
assessment of, 56
with cancer, 593–594
Quetiapine
for agitated delirium, 312–313, 312t
dosing and adverse events of, 358, 359t
for Parkinson disease and hallucinations, 360
for psychosis in dementia, 301–302, 302t
to stabilize mood in mania and bipolar depression, 340t

R
comprehensive assessment of, 157–158
case study, 157–158
conceptual model for, 153
coverage and services, 153–154
environmental modifications for, 162–165
goals of, 157, 158
of hearing loss, 217–218
outcomes, 154–155
postacute, 46
prosthetic, 162
sites of care, 152–153, 153–154, 153t, 154–155
for stroke, 158–159
teams and roles, 155, 156
vestibular rehabilitation therapy (VRT), 225
Rehabilitation Engineering and Assistive Technology Society of North America
Wheelchair Service Guide, 164
Rehabilitation hospitals, 152–153, 153t
Relafen (nabumetone), 136t
Relative exercise intensity, 69
Relaxation techniques
for anxiety disorders, 356
for sleep problems, 323t
Relaxation therapy, 100
Relaxation training, 356
Religion, 65
Religious identity, 63
Religious involvement, 26–27
Relistor (methylnaltrexone), 453t
REM sleep behavior disorder, 225
Renal artery stenosis, 464
Renal bone disease, 468–469
Renal replacement therapy, 469–470
Renin inhibitors, 443–444
Renovascular angioplasty, 465
Renovascular disease, 465
Repaglinide (Prandin), 572t
Repaglinide and metformin (PrandiMet), 573t
Reperfusion therapy, 420
Research
on cognitively impaired older adults, 32, 32t
informed consent for, 32
Resident Assessment Protocols, 239
Residential-care facilities, 7
Resistance training
interventions for preventing falls, 268t
recommendations for, 69, 71t
Resource utilization group system (RUGS), 46
Respect for life, 119
Respectful nonverbal communication, 64
Respiration, loud, 126
Respiratory diseases and disorders, 408–414
antibiotic therapy for infections, 539–540, 541t
chronic lower respiratory disease, 4–5, 6t
preoperative assessment and management of, 111
pulmonary disease, 409–414
symptoms and complaints, 408–409
Restless legs syndrome, 319–320
Restrants, 35, 149
for behavioral problems in dementia, 304
Retinal detachment, 202, 204t
Retinopathy, diabetic, 203t, 207–208, 209t
Retropulsion, 255t
Revascularization
for chronic CAD, 422–423
for peripheral arterial disease, 430
Review of systems at hospital admission, 143, 143t
Rheumatic mitral stenosis, 423
Rheumatoid arthritis, 501–502
Rheumatoid factor, 496
Rheumatologic diseases, 500–506
Rhinosinusitis, 408–409
Rhythm abnormalities, 267
Riboflavin, 234t
Rifampin, 545
Rimantadine, 543
Rimet (metformin), 572t
Rivastigmine
for dementia, 292–293
for dementia with mental retardation, 381
for dementia with Parkinson disease, 529, 530
RLS (restless legs syndrome), 319–320
Role loss and acquisition, 22–23
Rollators, 164
Rolling assessment, 52
Romberg test, 257
Ropinirole
for Parkinson disease, 529
for periodic limb movement disorder, 320
for restless legs syndrome, 320
Rosacea, 387–388, 387/388
Rosiglitazone (Avandia), 571, 573t
Rosiglitazone and glimepiride (Avandaryl), 573t
Rosiglitazone and metformin (Avandamet), 573t
Rotigotine, 529
Roxanol (morphine, immediate release), 136t
“RS3PE” syndrome (remitting seronegative symmetrical synovitis with pitting edema), 502
RUGS (resource utilization group system), 46
Rule of double effect, 33
S
S-adenosylmethionine (SAM-e), 98, 99t, 101
Sacral fractures, osteoporotic, 509
Sacral nerve neuromodulation, 251
Safe Return, 291–292
Safety, 84
attention to, 291–292
of CAM therapies, 98–99
and dementia, 291–292
of dietary supplements, 98, 99t
home safety evaluation, 269t
preventing injury, 84
in transitions, 178
Salix (salsalate), 136t
Salicylates, 235, 235t
Saline laxatives, 453t
Salivary function, 402
Salivary glands, 399, 400t
Salix alba (white willow bark), 100
SHBG (sex hormone-binding globulin), 561
SHC (Senior Health Clinic), 189
Sheltered housing, 188
Shenkui, 367
“Shingles” (herpes zoster), 204t, 205, 392–393, 393t, 548
Short Form-36 Health Survey (SF-36), 56, 205, 367
Shoes, 519
Short Form-36 Health Survey (SF-36), 56, 158
Shoulder pain, 497
Shy-Drager syndrome, 530
SIADH (syndrome of inappropriate antidiuretic hormone), 462, 558
Sick sinus syndrome, 425, 429
Sideroblastic anemia, 582
Sick sinus syndrome, 425, 429
Sjögren syndrome, 506
Skeletal system
age-related changes, 14t
age-related pathologies, 18t
Skilled nursing facilities (SNFs), 40t, 153t, 154, 155
Skin
age-related changes, 14t, 15, 386–387
age-related pathologies, 18t
Skin care, 329–330
Skin equivalents, 336
Skin problems
autoimmune conditions, 387–392
benign growths, 395–396
cancer, 80, 396–397
dermatologic diseases and disorders, 386–398
on foot, 519–521
infections, 392–394, 539–540, 541t
infections, 392–394
infestations, 392–394
inflammatory conditions, 387–392
neoplasms, 519–520
Sleep problems, 316–326
age-related changes, 316–317, 318t
CAM for, 101–102
causes of nocturia, 247t
central sleep apnea, 318
in dementia, 303, 320–321
epidemiology of, 316
evaluation of, 317
in hospitalized patients, 143t, 147t, 321
interventions for, 143t, 147t
management of, 322–326
measures to improve sleep hygiene, 322, 322t
nonpharmacologic interventions for, 322–323, 323t
in nursing home, 321–322
obstructive sleep apnea, 246t, 318–319, 321, 412–413
periodic limb movements, 319–320
pharmacotherapy for, 323–324
sleep apnea, 318–319
treatment of, 303
Sleep-related breathing disorders, 318–319
Sleeping medications, 321, 325–326
Sleep restriction, 323t
Sleeping medications, 321, 325–326
Slings, 251
Slowness, 198t
SLUMS (St. Louis University Mental Status) examination, 55, 286, 287t
Smell dysfunction
medications that cause, 405, 406t
nonpharmacologic causes of, 405, 406t
Smoking cessation
counseling, 82
recommendations for, 79t
Smellen charts, 54
SNPs (skilled nursing facilities), 40t, 153t, 154
Snellen charts, 54
Special needs plans, 40–41
Special needs, 49
Specialty care, geriatric, 26–27
Spirituality, 25–26
Spinal cord dysfunction, 535
Spinal deformities, 382–384, 383t
Spinal manipulation, 100
Spinal stenosis, 246t
Speech therapy, 40t
rehabilitation team role, 155, 156t
Spinal cord injury, 246t
Spinal cord dysfunction, 535
Spinal cord injury, 246t
SSRs. See Selective serotonin-reuptake inhibitors
ST (speech therapy), 40t, 155, 156t
Socially inappropriate behaviors, 35
Socioeconomic status, 3–4
Social Security, 3
SSI (Supplemental Security Income), 187
SSI (Supplemental Security Income), 187
St. John’s wort (Hypericum perforatum), 101
for depression, 346t
safety issues, 98, 99t
St. Louis University Mental Status (SLUMS) examination, 55, 286, 287t
St. Thomas’s Risk Assessment Tool (STRATIFY), 265–266
Stabilization, 373
Staffing patterns, 168–169

Index 635
Staphylococcus aureus, 542

STAR*D (Sequenced Treatment Alternatives to Relieve Depression), 342, 342

Starlix (nateglinide), 572t

Stasis dermatitis, 391–392

State Veterans Homes, 167

Statins
- for acute coronary syndrome, 420
- for atherosclerotic complications of diabetes mellitus, 570
- for chronic CAD, 421
- perioperative, 110, 114t

Stem cell/progenitor cell theory of aging, 11, 13

Stem cell/progenitor cell theory of aging, perioperative, 110, 114

Stress incontinence, 244
- and impaired urethral sphincter support, 246

Stress test, 110, 112t

Stress testing, preoperative, 110

Stressors, 20–23

Striatonigral degeneration, 530

Stroke
- acute ischemic, 525–526
- approach to management of, 158–159
- cardioembolic, 525
- goals of rehabilitation after, 158
- guidelines for rehabilitation after, 158–159
- incidence of, 523
- and incontinence, 246t
- NIH Stroke Scale, 158–159, 523, 523t, 526
- in nursing-home population, 166
- prevalence of, 4, 5f
- prevention of, 426–427, 525
- rehabilitation after, 158–159
- risk factors for, 523–524

Subdural hematoma, 526

Surfactant laxatives, 453t

Subclinical depression, 343–344

Subclinical glucocorticoid hypersecretion, 559

Subclinical hyperthyroidism, 553

Subclinical hypothyroidism, 551

Subconjunctival hemorrhage, 203–204, 204t, 205

Subdural hematoma, 526

Subluxation, foot, 515t

Suboptimal care transitions, 177–178

Substance abuse
- at-risk use, 369
- brief interventions for, 374
- counseling interventions for, 79t
- definition of, 369–370
- identifying substance-use disorders, 372
- outpatient management of, 373–374
- pharmacotherapy for, 374–376
- risks and benefits of, 371–372
- treatment of, 372–376

Substance dependence, 369

Substance-induced psychotic disorders, 361

Substituted judgment, 28, 30–31, 30t

Suicide
- physician-assisted, 33
- prevention of, 349t, 350

Superventricular arrhythmias, 427–428

Superventricular tachycardia, 429

Supplements, 237–238
- for pressure ulcers, 333
- safety issues, 98, 99t

Surfactant laxatives, 453t

Surgeons, 20–23

Systemic lupus erythematosus, 505

Systems of care, 142–193

Syphilis, 547–548

Sympathomimetic drugs, 350

Systolic hypertension, 350

Systematic assessment, 143

Symptoms, 196–338

Systemic lupus erythematosus, 505

Synecope, 227–232
- causes of, 227, 228t
- diagnosis of, 227
- evaluation of, 229–231
- history in, 229
- indications for permanent pacemaker implantation, 429–429, 429t
- natural history of, 227
- pathophysiology of, 227–229
- physical examination of, 229–231
- predictors of, 229, 229t
- prognosis for, 227
- reflex, 231
- signs and symptoms of, 227, 228t
- treatment of, 231–232
- vasovagal, 227, 228t

Sympathomimetic drugs, 350

Symptoms, 196–338

Surveillance, 485

Sustained-release forms, 342

Suspiciousness, isolated, 360
bowl obstruction in, 123–124
cachexia in, 124
constipation in, 122
cough in, 126
delirium in, 124
depression in, 124–125
diabetes in, 122–123
dyspnea in, 125–126
nausea and vomiting in, 122
palliative care, 122–126
Terminology
glossary of gait abnormalities, 255
preferred terms for cultural or religious identity, 63
shoe terms, 519
terms used in care of patients in pain, 130
Testamentary competence, 29
Testosterone, 560–562
Testosterone replacement therapy, 560–562
Testosterone, 560–562
screening test, 78
low thyrotropin, 552
Thyroid hormone requirements, 552
Thyroid hormone replacement, 551–552
Thyroid hormone replacement, 551–552
Thyroid disorders, 550–554
cancer, 553–554
with developmental disabilities, 382–384, 383
nodular, 553–554
screening for, 80
Thyroid hormone replacement, 551–552
Thyroid hormone requirements, 552
Thyroid-stimulating hormone (thyrotropin), 550
Thyroid ultrasonography, 553–554, 555
Thyrotoxicosis
apathetic, 552
triiodothyronine (T₃), 552
Thyrotoxicosis
apoliticoid, 550
Thyrotoxicosis
apathetic, 552
Triiodothyronine (T₃), 550
Triiodothyronine (T₃), 550–551
Tilt-table testing, 231
Time of death, 33–34
Timed Up and Go (TUG) test, 54, 258, 265
Timolol, 210
Tinnitus, 215
Tiotropium bromide, 411, 412
Tirofiban, 419
Tissue plasminogen activator (tPA), recombinant (alteplase), 525–526
TMP (trimethoprim), 235, 235
TMP-SMX (trimethoprim-sulfamethoxazole)
drug interactions, 93, 93
for UTIs, 544
Thyroid dependence, 82, 376
α-Tocopherol (vitamin E)
for dementia, 293
RDIs for adults ≥ 71 years old, 234
Tolerance, 134
Tolterodine, 250
Tolvaptan, 462
Tongue, black hairy, 405, 405
Toothlessness, 401–402
Topiramate, 534
Total hip and knee arthroplasty, 160–161
cause and surgical care of, 160–161
management of, 161
rehabilitation after, 161
Toxic or metabolic encephalopathy, 305

Systemic review, 143, 143

T-score, 275–276

T₁, See Triiodothyronine

T₄, See Thyroxine

Tarsal tunnel syndrome, 429

Tadalafil, 492–493, 493

Tachy-brady syndrome, 429

T₄.

for frailty, 200
for pain, 132
for preventing falls, 72, 266, 268 recommendations for, 71, 82
for sleep problems, 323

Tailor's bunion, 515

Tai Chi

for frailty, 200
for pain, 132
for sleep problems, 323

for preventing falls, 72, 266, 268
table

Teach-back method, 63

Teaching problems. See Cognitive impairment

32P, 585–586

Thought disorder, 357

Thromboembolism
pulmonary, 413–414
venous, 115, 116, 431–432

Thrombolyphia, 584

Thrombophrophylaxis

guidelines for, 115, 116, 148
in hospitalized patients, 143, 148

Thrombotic thrombocytopenic purpura, 583

Index 637
Toxicity, chemotherapy, 591, 592
Tradition, 64–65
Traditional Chinese medicine, 97
Traditional Native American medicine, 98
Tradjenta (linagliptin), 572
Tramadol (Ultram), 137t, 138
Trandolapril, 435
Transesophageal echocardiography,
Transdermal fentanyl (Duragesic), 137–138
Tramadol (Ultram), 137–138
Tradjenta (linagliptin), 572
Traditional Native American medicine, 98
Traditional Chinese medicine, 97
Tradition, 64–65
Toxicity, chemotherapy, 591, 592
for depressive features of behavioral
for depression, 346t
for depressive features of behavioral
disturbances in dementia, 299–
300, 300t
and incontinence, 245t
for persistent pain, 135t, 137–138
Triiodothyronine (T3), 344, 346t
low T3 syndrome, 551–552
Triiodothyronine (T3) thyrotoxicosis, 552
Trimethoprim (TMP), 235, 235t
Trimethoprim-sulfamethoxazole (TMP-
SMX)
drug interactions, 93, 93t
for UTIs, 544
Tropium, 250
Truth telling, 35
TTP (thrombotic thrombocytopenic
purpura), 583
Tube feeding, 241, 242
Tuberculosis, 544–545
Tubular necrosis, acute, 466
TUG (Timed Up and Go) test, 54, 258, 265
Turn en bloc, 255
Tylenol (acetaminophen), 135t
Tylox (oxycodone, immediate release), 138
Tylenol (acetaminophen), 135
Tylenol (acetaminophen), 137
Tylenol (acetaminophen), 137
Urinary incontinence (UI), 244–253
assessment of, 251
behavioral therapies for, 249–250,
251, 252
CAM for, 102
comorbid conditions that can cause or
worsen, 245, 246t
with developmental disabilities,
382–384, 383t
evaluation of, 247–249
functional, 244
history in, 247
with impaired bladder emptying, 246
from incomplete emptying, 244
lower urinary tract pathophysiology
in, 245–246
management of, 249–251
medications that can cause or worsen,
245, 245t
minimally invasive procedures for,
251
mixed UI, 244, 246
in nursing-home residents, 251–252
pathophysiology of, 245–246
physical examination with, 247–248
prevalence and impact of, 244
prevention of, 83
red flag symptoms, 247
risk factors for, 245
screening for, 79t, 247, 251
stress UI, 244, 246
supportive care for, 251
surgery for, 251
testing for, 248–249
transient, 244
treatment of, 249–251
types of, 244
urge UI, 244, 245–246
Urinary system
age-related changes, 14t, 16–17
age-related pathologies, 18t
Urinary tract infections, 543–544
antibiotic therapy for, 539–540, 541t
in men, 543, 544
in women, 543, 544
Urodynamics testing, 249
Urogenital atrophy, 473–474
U.S. Department of Agriculture (USDA),
233
U.S. Department of Health and Human
Services (HHS), 71, 72
U.S. Preventive Services Task Force
(USPSTF), 72, 73, 76, 77–80, 81, 82
Indications for osteoporosis screening, 276, 276t
Recommendations for BMD testing, 276
Recommendations for prostate cancer screening, 482
USDA (U.S. Department of Agriculture), 233
USPSTF. See U.S. Preventive Services Task Force
Uveitis, 203, 204t

Vaccinations
H1N1, 543
herpes zoster, 78t, 85, 539, 540t
for hospitalized patients, 143t, 148
for influenza, 78t
for respiratory patients, 175
in nursing-home care, 175
pneumococcal, 78
for influenza, 78
for hospitalized patients, 143
herpes zoster, 78
H1N1, 543

Vacuum tumsence devices, 493, 493t
Vaginal atrophy, 488
Vaginal bleeding, postmenopausal, 477, 477t
Vaginal dryness, 102
Vaginal prolapse
classification of, 475–476, 475t
surgery for, 476–477
Valerian, 326
Valerian root, 101
Valgus position, 515t
Valproic acid (valproate, divalproex), 294, 294t
Valgus position, 515t
Valproic acid (valproate, divalproex), 294, 294t
Valproic acid (valproate, divalproex), 294
Valproic acid (valproate, divalproex), 294
Valproic acid (valproate, divalproex), 294

Venlafaxine (Effexor)
for depression, 344, 346t
for depressive features of behavioral disturbances in dementia, 299–300, 300t
for persistent pain, 135t
Venous thromboembolic disease, 431–432
Venous thrombosis prophylaxis guidelines for, 115, 116t
in hospitalized patients, 143t, 148
Venous ulcers, 392, 392t
Ventricular arrhythmias, 428
Venues for care, 179
Verapamil
adverse drug events, 92, 92t
for atrial fibrillation, 426
drug interactions, 93, 93t
Verbal Descriptor Scale, 129
Vertebral fracture assessment (VFA), 276–277
Vertebral fractures
compression fractures, 282–283
management of, 282–283
osteoporotic compression fractures, 508–509
Vertebroplasty, 283
Vertigo, 221, 223t
benign paroxysmal positional vertigo (BPPV), 221, 224, 224t, 225
VES-13 (Vulnerable Elders Survey-13), 192
Vestibular rehabilitation therapy (VRT), 225
Veterans Administration (VA), 43, 191
Veterans Affairs, Department of

guidelines for rehabilitation after stroke, 158–159
hearing aid benefits, 219
VFA (vertebral fracture assessment), 276–277
Vicodin (hydrocodone), 136t
Vicoprofen (hydrocodone), 136t
Victoza (liraglutide), 573
Videofluoroscopic deglutition examination (VDE), 240, 241
Vilazodone
for depression, 346t
for depressive features of behavioral disturbances in dementia, 300t
VIN (vulvar intraepithelial neoplasia), 475
Vinorelbine, 591
Viral conjunctivitis, 203–204, 204t
Visceral pain, 129, 131t
Vision services, 40t
Vision testing, 79t, 83–84, 202
Visual Analog Scale, 337
Visual imagery, 356
Visual impairment, 202–211
assessment of, 54–55
definition of, 202
low-vision rehabilitation, 210
preventing falls with, 267, 268t
rapid screening followed by assessment and management of, 52, 53t
screening for, 79t, 83–84
signs and symptoms requiring immediate referral, 202–203, 204t
sudden decrease in vision, 202, 204t
symptoms and treatment of common eye diseases, 203t, 204t

Vitamin A
drug interactions, 235, 235t
RDIS for adults ≥ 71 years old, 234t
Vitamin B12, 235, 235t
Vitamin B12, 235, 235t
Vitamin B6, 235, 235t
Vitamin B6, 235, 235t
Vitamin B12 replacement, 583
Vitamin B12 replacement, 583
Vitamin B12 supplements, 237
Vitamin B6 supplements, 237
Vitamin B12 supplements, 237
Vitamin B12 deficiency, 581
hypoproliferative anemia due to, 581, 581t
and incontinence, 246t
Vitamin B12 replacement, 583
Vitamin B12 replacement, 583

Index 639
Vitamin C
for AMD, 206
RDIs for adults ≥ 71 years old, 234

Vitamin D
drug interactions, 235
for malnutrition, 237
for osteoporosis, 273
for prevention of falls, 267
for vitamin D deficiency, 555–556
RDIs for adults ≥ 71 years old, 234
for osteoporosis, 278
for prevention of falls, 267
preventive, 79, 85
Vitamin D insufficiency, 273
Vitamin D3 (cholecalciferol) supplements
to reduce risk of osteoporosis, 274
for vitamin D deficiency, 555–556
Vitamin E (α-tocopherol)
for ARMD, 206
for dementia, 293
drug interactions, 235
Vitamin E supplements, 237–238
Vitamin K
drug interactions, 235
RDIs for adults ≥ 71 years old, 234
Vitamin therapy
for ARMD, 206
multivitamin supplements, 79, 85
Volume depletion, 558
Vomiting. See Nausea and vomiting
von Willebrand disease, 584
Vulnerable Elders Survey-13 (VES-13), 192
Vulvar disorders, 474–475
Vulvar excoriation, 474
Vulvar intraepithelial neoplasia, 475
Vulvar lesions, nonneoplastic, 474–475
Vulvar neoplasia, 475
Vulvodynia, 474
Vulvovaginal atrophy, 474
Vulvovaginal infection and inflammation, 474

W
Walkers, 163–164
Walking, 71
limitations in, 254

in nursing-home population, 166
6-minute walk test, 257–258
Wandering, 35
Warfarin therapy
for acute coronary syndrome, 420
adverse drug events, 92, 92
for atrial fibrillation, 426–427
drug interactions, 93, 93
recommendations for cessation before surgery, 110
for stroke prevention, 525
for venous thromboembolic disease, 431–432
Watchful waiting, 484, 485
Water balance, 558
Weakness, 190
Weight loss
anorexia, 124
for chronic CAD, 421
definitions that define frailty, 190
definition of, 234
for musculoskeletal diseases and disorders, 499
unacceptable, 238–239
Weight management, 72
Weight screening, 78, 84
Westergren erythrocyte sedimentation rate, 496
Wheelchairs, 164
Wheelzing, 409, 410
WHI (Women’s Health Initiative), 563
Whisper-voice test, 55, 84, 145
White Americans
alcohol use, 371
cancer diagnosis and survival, 589
cancer incidence, 589
diabetes mellitus, 566
end-of-life care, 119
hypertension, 440
leading causes of death, 4–5
life expectancy, 3, 3
menopausal symptoms, 102
RDIs for micronutrients, 233–234
recommendations for BMD testing, 276
recommendations for dietary calcium intake, 278
recommendations for vitamin D, 278
sexual dysfunction, 82
stroke in, 523
urinary incontinence, 245
urinary tract infections in, 543, 544
Women’s Health Initiative (WHI), 563
Wong-Baker FACES Pain Rating Scale
with Foreign Translations, 129
World Health Organization (WHO)
BMD definitions, 271, 272
definition of osteoporosis, 271
diagnostic criteria for anemia, 577
fracture risk assessment model (FRAX™), 271, 273
International Classification of Functioning,
Disability, and Health (ICF), 152
Three-Step Analgesic Ladder, 133, 134
Three-Step Analgesic Ladder, 133, 134
Wound care, 327–338
Wound healing
cascade of, 327–328
inflammatory phase, 327
maturation phase, 328
monitoring, 336
Pressure Ulcer Scale for Healing, 336
proliferative phase, 327
| Wrist pain | Zaleplon | for psychosis in dementia, 301–302, 302t |
| chondrocalcinosis of, 503, 503t | for insomnia, 324, 325t | Zoledronic acid, 278–279, 279t, 280 |
| evaluation of, 497–498 | for sleep disturbances in dementia, 303 | Zolpidem |
| X | Zanamivir, 543 | and delirium, 311t |
| Xerosis, 388, 520 | Zinc | drug interactions, 93, 93t |
| Y | for AMD, 206 | for insomnia, 324, 325t |
| Yergason sign, 497 | drug interactions, 235, 235t | for sleep disturbances in dementia, 303 |
| Yoga, 71, 71t | RDIs for adults ≥ 71 years old, 234t | Zonisamide, 534t |
| Z | Ziprasidone | dosing and adverse events of, 358, 359t |